[
  {
    "objectID": "evidence_tables.html",
    "href": "evidence_tables.html",
    "title": "Evidence Tables",
    "section": "",
    "text": "Study\n      Enrolled\n      Inclusion/Exclusion Criteria\n      Results\n      Note\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Zhang 2018\n\n392\nInclude: Age >=65 and <90 years; primary cancer without any radio- or chemotherapy before surgery; scheduled to undergo surgery for cancer with an expected duration >=2hrs under general anesthesia.Exclude: History of schizophrenia, epilepsy, Parkinsonism, or myasthenia gravis; inability to communicate in the preoperative period because of coma, profound dementia, language barrier, or incapacity from severe disease; critical illness (ASA status >III), severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery); or neurosurgery.\n\nThe incidence of delayed neurocognitive recovery at 1 week was lower in the propofol group [14.8%(28/189)] than in the sevoflurane group [23.2%(44/190)]; OR=0.58 (95% CI: 0.34-0.98).\n\"[P]respecified analysis of one center\" from 17 participating centers\n    Sauer 2014\n\n737\nInclude: Age >18 yrs; undergoing cardiopulmonary bypass.Exclude: Emergency surgery; scheduled for an off-pump technique; patients with a life expectancy of <6months.\n\nThe intraoperative admin of dexamethasone did not reduce the incidence or duration of delirium in the first 4 days after cardiac surgery.\nA substudy of DECS trial\n    Ottens 2014\n\n291\nInclude: Age > 18 yrs;.Exclude: Vision impairments; hearing or motor impairment; mental illness.\n\nAt 1-month follow-up, 13.6% in the dexamethasone group 7.2% in the placebo group were diagnosed with POCD (relative risk, 1.87; 95% CI, 0.90 to 3.88; P = 0.09). At 12-month follow-up, 7.0% in the dexamethasone group and 3.5% in the placebo group had POCD (relative risk, 1.98; 95% CI, 0.61 to 6.40; P = 0.24).\n\n    Whitlock 2015\n\n7507\nInclude: Age >=18; EuroSCORE >=6 (Jul 2011, China and India included EuroSCORE>=4); cardiac surgery requiring cardiopulmonary bypass.Exclude:  Not specified.\n\nDifferences were not detected in 30-day mortality between patients receiving methylprednisolone (154/3755, 4%) compared with patients receiving placebo (177/3752, 5%), (RR, 95% CI: 0.87, 0.70-1.07). Differences were not detected in delirium by day 3 between patients receiving methylprednisolone (295/3755, 8%) compared with patients receiving placebo (289/3752, 8%), (RR, 95% CI: 1.02, 0.87-1.19).\n\n    Zhu 2021\n\n187\nInclude: Age >= 65 yrs; ASA II-III; no anesthesia contraindications.Exclude: Mental illness; MoCA score <= 26; coronary heart disease; diabetes; hypertension; liver malfunction; renal failure; coagulation dysfunction; use of antidepressants or beta blockers.\n\nMean MMSE score 48 hours post operation in the dexmedetomidine group was higher (27.15±1.17) compared to control group (23.11±0.83, p<0.05).\n\n    Mansouri 2019\n\n150\nInclude: > 65 years of age; ASA I and II characteristics; No history of sensitivity to anesthetics; No history of moderate to severe mental disorders;.Exclude: Occurrence of severe hemodynamic disorder during the surgery leading to a change in anesthesia; extended surgery duration for >1 hour; Sensitivity to the anesthetics.\n\nNo statistically significant difference between the midazolam and dexmedetomidine groups in the MMSE score 24 hours after surgery (14% vs 12%, respectively) and 1 week postop (8% vs 12%, respectively; P > 0.05). However, there was a significant difference between these two groups and the control  (8% for Midazolam, 12% for Dexmedetomidine vs 20% Control; P < 0.05).\n\n    Forsmo 2016\n\n653\nInclude: Patients >18 years; scheduled for elective open or laparoscopic colorectal surgery for malignant or benign diseases, with or without stoma; rectal cancer who had pelvic radiation.Exclude: Patients with a planned multivisceral resection; ASA class IV; pregnancy; emergency operations; impaired mental capacity.\n\nTotal hospital stay was significantly shorter among patients randomized to ERAS than among the standard group.  The two treatment groups exhibited similar outcomes regarding overall major and minor morbidity, reoperation date, readmission rate, and 30-day mortality.\n\n    Watne 2014\n\n329\nInclude: All patients admitted with a hip fracture.Exclude: Moribund on admission or patients with high energy trauma.\n\nThere was no difference in cognitive function four months after surgery between patients in the comprehensive geriatrics assessment group and standard care group (Clinical Dementia Rating Scale 54.7 versus 52.9, 95% CI: −5.9 to 9.5; p=0.65). Postoperative delirium was seen in 49% in the intervention group and 53% in the standard care group (p=0.51).\n\n    Hempenius 2016\n\n297\nInclude: Age > 65 yrs with Groningen Frailty Indicator > 3 (frail).Exclude: Unable to fill out questionnaires or comply with follow-up visits.\n\nOverall incidence of postoperative delirium in this clinical trial was 11.5% (26/227). There was no difference in the MMSE score at discharge between the standard care group and multicomponent preoperative assessment group (26.5 vs 26.9, p=0.97). The Short Form-36 physical component measure were similar in both groups, respectively (49.3 vs 48.4, p=0.17).\nLiaison Intervention in Frail Elderly (LIFE), was a multicenter, randomized clinical trial in the Netherlands. Primary outcome of postoperative delirium is not reported by study groups but by mortality.\n    Mei 2020\n\n415\nInclude: Age >=65; undergoing total knee arthroplasty; ASA I to IV.Exclude: Contraindications to spinal anesthesia (i.e., coagulopathy, infection at puncture site, and refusal of spinal anesthesia); having a mental or language barrier; patients with infections; patients who had been anesthetized within the past 30 days; history of congestive heart failure (New York Heart Association, class IV); and/or severe chronic obstructive pulmonary disease (Global Initiative for Chronic Obstructive Lung Disease Guidelines, stages III to IV); diagnosis of sick sinus syndrome; severe sinus bradycardia (<50 beats/min); and second or greater atrioventricular block without pacemaker; patients exhibiting cognitive impairment (i.e., a MMSE score <24) and/or perioperative delirium (i.e., CAM result).\n\nPts who received dexmedetomidine sedation had lower incidences of POD (odds ratio: 0.54; 95%CI: 0.31-0.92; P=0.032). In addition they had better postoperative cognitive function than patients sedated with Propofol on the third (24.3 ± 3.9 vs 22.1 ± 4.3; P<0.001, respectively) and seventh (25.6 ± 4.8 vs23.3 ± 3.3; P<0.001, respectively) day postoperatively.\nFigure 1 shows the flowchart for the patient enrollment and randomization, but does not specify which groups is the control and which is the intervention.\n    Du 2019\n\n87\nInclude: Age ≥ 65; ASA I-II;.Exclude: Dxof cognitive dysfunction; dxof psychosis; dxof severe cardiac disease; dx of lung disease; dx of liver disease; dx of renal disease; dx of any other system disease; surgery time >1h; surgery could not be accomplished successfully and turned into laparotomy operation.\n\nPostoperative cognitive dysfunction was greater in the control group compared to the dexmedetomidine group. MMSE scores were lower in the control group compared to the dexmedetomidine group at 12h (19.4±1.8 vs 22.4±1.9), 24h (22.3±1.4 vs 23.7±1.3), and 48h (24.1±1.1 vs 25.0±1.5) postop (P<0.05).\n\n    Tang 2021\n\n100\nInclude: Patients age 60-85 years; ASA status I-II; laparoscopic radical resection of rectal cancer.Exclude: History of neurological or mental illness; drug allergy; alcoholism; use of anticoagulants, NSAIDS, or hormones 3 months prior; blood loss during operation >20% basal blood volume; intractable hypotension; anaphylactic shock.\n\nIn patients undergoing laparoscopic radical resection of rectal cancer, patients recevieving dexmedetomidine experienced higher cognitive scores through 48 h postsurgery compared with patients receiving placebo (p<0.05).\n\n    Xing 2021\n\n110\nInclude: Age >= 60 yrs; ASA I-II.Exclude: Cognitive dysfunction; cardiopulmonary abnormalities; coagulation disorders; concomitant immune system and endocrine system disease.\n\nThe incidence of delirium 24 hours post operation was lower in the dexmedetomidine group compared to controls (3.6% vs 14.5%, p<0.05).\n\n    Mahrose 2021\n\n110\nInclude: Patients of both sexes above age 60; written informed consent.Exclude: Preoperative mental illness; emergency procedures; preoperative renal failure; diagnosis of chronic liver disease; diagnosis by carotid duplex to have carotid disease; prolonged postoperative intubation and re-exploration.\n\nIncidence of delirium was lower, onset was more delayed, and duration was shorter in the dexmedetomidine + oral melatonin group (group -DM) compared to the dexmedetomidine alone group (group-D).\n\n    Tu 2021\n\n80\nInclude: Patients age >=60 years; ASA status I-III.Exclude: Hepatic and renal dysfunction; coagulation dysfunction; infectious disease; blood system diseases; increased blood lactic acid or metabolic diseases; end-stage chronic diseases; active bleeding; severe pulmonary hypertension, heart failure and acute myocardial infarction; surgical contraindications; anesthesia contraindications; severe infections; functional abnormality of important organs; mental disorders or psychological illness.\n\nIn patients undergoing spinal surgery, patients induced with propofol and esketamine experienced higher neurocognitive scores (Montreal Cognitive Assessment) at 24 h postop compared with patients induced with propofol and sufentanil, mean (SD) of 21.8 (1.5) vs 17.4 (0.9), p<0.05.\nThis study administered esketamine (not ketamine).\n    Li 2020\n\n87\nInclude: Patients with lung cancer diagnosis willing to receive surgical resection.Exclude: Received prior radiotherapy or chemotherapy; other malignant tumors; liver or kidney dysfunction; communicative or cognitive impairment.\n\nIn patients undergoing lung resection, a difference was not detected in neurocognitive scores among patients receiving dexmedetomidine with conventional anesthesia intraoperatively (n=41) compared with patients receiving conventional anesthesia alone (n=46) (MMSE scores: 27.3 +/- 2.5 vs 27.2 +/- 3.1, p=0.8).\n\n    Wang 2020\n\n110\nInclude: Diagnosed with gastric cancer and consented to surgical resections; no radiotherapy, chemotherapy, or comorbidity with other malignant tumors.Exclude: Liver and renal disfunction; communication and cognitive dysfunction.\n\nThe number of postoperative cognitive dysfunction of patients in the experimental group was lower than that of patients in the control group (P<0.05). The total number of adverse reactions in the control group was higher than that of patients in the experimental group (P<0.05). The MMSE scores of the two groups were decreased at 1 day after operation and were significantly lower in the control group than in the experimental group (P<0.05).\nText says a total of 100 patients, but there are 60 in the experimental group and 50 in the control?\n    Zhou 2019\n\n156\nInclude: Patients age 60-80 years; ASA status I-III; heart valve replacement surgery.Exclude: MMSE <=23; acute or chronic infectious disease; use of infammatory  drugs or immunosuppressants; stroke in past 6 months or other central nervou system disease; ICU >=3 days; BMI >35; severe deafness or vision problems; communication difficulties; postoperative delirium.\n\nIn patients undergoing heart valve replacement surgery, patients receiving ulinastatin alone (n=39), dexmedetomidine alone (n=38), and ulinastatin plus dexmedetomidine (n=39 ), experienced less postoperative cognitive dysfunction after 7 days of followup compared with patients receiving saline (n=38), incidences of 18%, 16%, and 10% vs 32%, p<0.05.\n\n    Wang 2019\n\n198\nInclude: >= 65 years of age; ASA status of I, II, or III; operative time of about 2-4 hours, with the ability to complete MMSE; preoperative MMSE score >15; no significant evidence of serious central nervous, cardiovascular, respiratory, etc; no contraindications to dexmedetomidine or midazolam; no history of  antidepressant usage, benzodiazepine, alcohol, cigarette misuse, drug dependence;.Exclude: Preoperative bradyarrhythmia (HR < 50 bpm); central nervous system or mental disease; use of sedatives or analgesics recently; renal and/or hepatic dysfunction; chronic alcohol or drug abuse; life expectancy of less than three months; massive blood loss (>1500 mL); MMSE score <15 before surgery; refusal to participate in study;.\n\nDexmedetomidine can reduce neuronal injuries but cannot reduce incidence of postoperative cognitive dysfunction/decline (POCD) in the elderly, compared with midazolam.\n\n    Gupta 2019\n\n100\nInclude: Age >= 65 yrs; ASA I-II.Exclude: Dementia; severe infection; intracranial bleed; acute cardia event.\n\nThe incidence of delirium in Ramelteon group was lower in comparison with placebo group (4% vs 12%).\n\n    He 2018\n\n90\nInclude: Age 75-90; ASA grade I-III; receiving selective operation; dx of thoracic or lumbar vertebral fractures.Exclude: Pts gaining <=23 points in the MMSE; taking sedatives; taking antipsychotics; dx of mental illness; dx of central nervous system illness; unable to effectively communicate; dx of severe heart disease; dx of severe lung disease; dx of severe brain disease; dx of severe liver disease; dx of severe kidney disease; dx of severe disease to any other important organ; dx of severe vision impairment; dx of severe hearing impairment; allergies to the drugs used in the study; those not suitable for this study.\n\nThe incidence rate of POD in the dexmedetomidine group was apparently lower than those in both the midazolam and control groups (F=38.731; p<0.001); the incidence rate of POD at 1-2 days after operation in the midazolam group was higher than the control group (F=26.759; p=0.003 vs F=17.685; p=0.031); there was no significant difference in the incidence rate of POD at 3-5 days after operation between the midazolam and control group (F=4.716; p=0.528 vs F=3.681; p=0.815; vs F=6.257; p=0.482).\n\n    Azeem 2018\n\n70\nInclude: Age >=60; ASA I-II; 70-100kg body weight; height 160-180 cm; undergoing elective cardiac surgery under general anesthesia.Exclude: Allergy to any drugs of the study; hx of drug abuse; hx of alcohol abuse; hx of uncontrolled diabetes; hx of hypertension; hx of chronic pain; daily intake of analgesics within 24 h before surgery; impaired kidney function; impaired liver function.\n\nDifferences were not detected in delirium following cardiac surgery between the Dexmedetomidine group and the midazolam with morphine group (3.33%, n=1 vs 6.67%, n=2, respectively; p=1).\nNote that what is written in the abstract box is opposite to what the results section notes (i.e., abstract box notes significance where results notes no difference being detected).\n    Xuan 2018\n\n453\nInclude: Patients age >60 years; joint replacement surgery under general anesthesia admitted to ICU.Exclude: Unsalvageable patients on admission; high cholesterol and diabetes; brain injury or neurosurgery; severe sinus bradycardia; sick sinus syndrome; neurologic disease; abnormal liver enzymes, rhabdomyolysis, and myopathy; mental illness or epilepsy; severe lung disease or multiple organ dysfunction.\n\nIn patients undergoing TKA or THA, patients receiving dexmedetomidine for up to 3 days postop experienced less postoperative delirium compared with patients receiving placebo, 30/227 (13%) vs 64/226 (28%), OR 0.39 (95% CI, 0.24-0.62), p<0.0001.\n\n    Ozer 2017\n\n88\nInclude: Age >64; elective OPCAB surgery.Exclude: More than 50% carotid artery stenosis; severe chronic obstructive pulmonary disease (COPD) requiring daily therapy with steroids or bronchodilators; renal insufficiency (creatine concentration >150 mmol liter 1); severe liver disease (alanine aminotransferase or aspartate aminotransferase >75 IU liter-1); a history of allergy to propofol; a history of seizure or stroke; preoperative MMSE score of >23.\n\nWe believe that well-performed hemodynamic stability with either intravenous or general anesthesia may offer a well-controlled mental function in elderly patients undergoing off-pump CABG surgery.\nNo registration or dates provided.\n    Yu 2017\n\n92\nInclude: Age >60 yrs; ASA I-II.Exclude: Senile dementia; coronary heart disease; hypertension; severe hepatic and renal dysfunction; other disease.\n\nPostoperative delirium occurrence rate of 6.52% in dexmedetomidine group was significantly lower than that in the control group, and the difference between the two groups had statistical significance (p <0.05).\n\n    Fan 2017\n\n76\nInclude: Not stated.Exclude: Not stated.\n\nIncidence of delirium was greater in the control group compared to the observation group, 6/38 (16%) vs 1/38 (3%), respectively.\n\n    Ge 2016\n\n50\nInclude: Diagnosis of carotid stenosis of >=70% with or without symptoms; no prior hx of undergoing carotid surgery.Exclude: MMSE score <20; pt undergoing emergency surgery; pt refusal to general anesthetic; pt undergoing treatment with psychiatric drugs;.\n\nMMSE scores were lower POD1 compared to 1 day prior to surgery for both groups (Control 25.80 vs 26.88; Dexmedetomidine 26.09 vs 27.18; p<=0.001. MMSE scores were higher in the dexmedetomidine group at 48 hours and 72 hours post-op compared to the control group (26.72 vs 25.87; p=0.025 and 27.10 vs 26.39; p=0.03, respectively).\n\n    Šakić 2015\n\n60\nInclude: Elderly patients with well-defined fracture femur for surgical procedure in spinal anesthesia (they never define the age criteria).Exclude: Diagnosis of diabetes mellitus, diagnosis of an autoimmune disease, corticosteroid and immunosuppressive use.\n\nDexamethasone group had less patients develop postoperative cognitive impairment compared to the levobupivacaine group, (17% vs 72%, respectively).\n\n    Mohamed 2014\n\n58\nInclude: >60; ASA class I to III; elective abdominal surgery expected to be longer than 2 hours; hospital stay >48hrs; educable.Exclude: High vagal tone (heart rate <60); arrhythmic disorders; severe ventricular dysfunction (EF <35%); hypovolemic patients; any psychological disorders; preexisting cognitive impairment; alcohol or drug abuse; preexisting CNS deficit; neurological symptomatic disorder confirmed by MRI.\n\nThe use of Dexmedetomidine as an adjuvant during Sevoflurane anesthesia did not have significant effect on protection against POCD in one day and one week postoperatively. The anesthetic and analgesic sparing effect of Dexmedetomidine was significantly proved by lower Sevoflurane need and significant lesser amount of total 24 hours postoperative Fentanyl requirements, but with significant prolonged extubation and orientation times in Dexmedetomidine group than placebo group.\n\n    Mardani 2013\n\n110\nInclude: Did not specify.Exclude: Illiteracy; prolonged intubation; >3hrs of CPB; >80 yrs; EF lower than 20% hemodynamic instability; hx of delirium; Emergency Operation; >24hr intubation postoperatively.\n\nDelirium and hospital length of stay significantly decreased in the dexamethasone group compared to the placebo in the first postoperative day (4(9.3%) vs. 13 (26%), p=0.03; 12.93 ± 1.03 vs 13.64 ± 1.75 days, p=0.02, respectively).\n\n    Liu 2016\n\n200\nInclude: Age 65-80; ASA II-III; total hip arthroplasty or total knee arthroplasty.Exclude: Neurological diseases that may affect cognitive function (subdural hematoma, vascular dementia, B12 deficiency, encephalitis); hypoxic pulmonary disease; perioperative serious cardiopulmonary complications.\n\nIn patients with amnestic mild cognitive impairment (aMCI) undergoing THA or TKA, patients administered dexmedetomidine experienced less postoperative delirium compared with patients receiving placebo, 10/39 (26%) vs 25/40 (63%), p<0.01. In patients without aMCI, patients administered dexmedetomidine experienced less postoperative delirium compared with patients receiving placebo, 5/60 (8%) vs 18/58 (31%), p<0.01.\nA subgroup analysis on age showed increased risk in patients aged >=75 with aMCI who were not treated with dexmedetomidine.\n    Yang 2019\n\n104\nInclude: Patients who met lung cancer diagnostic criteria; age >= 60; no contraindications to surgery and anesthesia; gave informed consent; >9 years of education in China;.Exclude: Patients with cardio-cerebrovascular diseases; abnormal lung function; cognitive disorders; history of drug dependence;.\n\n24 hours after the surgery, lung function indices of the sevoflurane group like FEV1, FVC, and VC were higher than those of the propofol group. At the end of the surgery and 24 hours after the surgery, MMSE scores were higher in the sevoflurane group than in the propofol group. Levels of NOX2 and NOX4 proteins in peripheral mononuclear cells were lower in the sevoflurane group compared to the propofol group.\n\n    Hongyu 2019\n\n90\nInclude: Age 65-80 years; tumor grade I-III; BMI 18.5-23.9; lung cancer.Exclude: Patients with glaucoma, cataract and other eye diseases; patients with central nervous system and psychiatric disorders, linguistically ineffective communication with psychologists; mini-mental state examination (MMSE) scores ≤23 points.\n\nMean MMSE score in elderly patients given penehyclidine hydrochloride was higher on POD 1 (24.7 vs 23.8; p<0.05) and lower POD 4 compared to controls (16.7 vs 23.5; p<0.001). Postoperative delirium was seen in 10% of PHH patients on POD 1 and 26.7% on POD 4 compared to 13.3% in controls.\n\n    Bornemann-Cimenti 2016\n\n60\nInclude: Patients age >18 years; ASA status I-III; weight between 40-120 kg; elective major open abdominal (colorectal and hepatic) surgery.Exclude: Acute or chronic pain treated with opioid therapy; severe kidney or liver dysfunction; alcohol or opioid addiction; present or past psychotic disorders.\n\nIn patients undergoing open abdominal surgery, patients receiving low-dose ketamine experienced higher delirium compared with patients receiving minimal-dose ketamine or placebo (p=0.007). Patients receiving low-dose and minimal-dose ketamine used less opioid compared with patients receiving placebo (p<0.05). Opioid use did not differ between the low-dose and minimal-dose ketamine groups (p=0.59).\n\n    Fazel 2017\n\n60\nInclude: Patients >65 years; ASA class I, II, III.Exclude: Patients with MMSE <23; inadequate education to complete the neuropsychological test; severe visual and hearing impairment; a history of known psychological disorders; consumption of antipsychotic, anti-anxiety, and anti-depression medications; consumption of alcohol; a history of mental illness, addictions, sensitivity to anesthetic medications or unwillingness to cooperate.\n\nPostoperative cognitive function in the sevoflurane group was significantly better than the propofol group in the 6-12 and 12-24 hours after surgery, but the assessment of the two groups in 24-48 hours after surgery showed similar conditions.\nThe registration says the age range is 55-65, but the article says 65+\n    Turan 2020\n\n798\nInclude: Age 18-85 yrs.Exclude: Sick-sinus or Wolff-Parkinson-White syndrome; allergy to dexmedetomidine; hepatic disease; atrial fibrillation; permanent pacemaker; MI within 7 days; severe heart failure; BMI >+ 40 kg/m2; clonidine within 48 hours.\n\nThe incidence of delirium was higher in patients given a placebo compared to dexmedetomidine (12% vs 17%; RR 1.48, 97.8% CI: 0·99–2·23). Atrial arrhythmia was also higher in patients given a placebo (30% vs 34%; RR 0.91, 97.8% CI: 0.72-1.15).\nDECADE is a multi-center randomized controlled trial across 6 academic medical centers in the USA and funded by Hospira Pharmaceuticals.\n    Wu 2020\n\n80\nInclude: Age 40-75 yrs; ASA II-III; carotid stenosis.Exclude: Cognitive dysfunction; mental disorders; cerebral infarction or intracranial hemorrhage.\n\nThe MMSE scores in both groups increased at 1 and 7 days postoperatively; although the increase in the dexmedetomidine group was sharper, there was no significant difference.\n\n    Wang 2020\n\n44\nInclude: Currently using a nasal tracheal duct in ICU postop; required sedative treatment; age >= 18; ASA I or II.Exclude: Dx liver dysfunction; dx of kidney dysfunction; ALT exceeding 3x the upper limit of normal as indicator of liver damage; Serum creatinine and urea nitrogen exceeding the upper limit of normal as indicator of impaired renal function; acute myocardial infarction or severe heart failure; drug dependence; alcoholism' hx of psychological illness; severe cognitive dysfunction; currently pregnant or lactating; allergic to midazolam; allergic to dexmedetomidine.\n\nThe incidence of delirium in the dexmedetomidine group was significantly lower than in the midazolam group (1 (1.5%) vs 9 (45%), respectively; P=0.003).\nAuthors were emailed to inquire what scale was used to measure delirium.\n    Yan 2021\n\n100\nInclude: Age 60-85 yrs; ASA I-II.Exclude: Dementia, schizophrenia, or depression; use of psychotropic drugs; stroke; alcohol abuse; smoking.\n\nThe incidence of postoperative delirium in the dexmedetomidine group was lower than that in control group (10% vs 26%; p=0.037). The duration of delirium (1.3 6 0.6 days) was shorter in the dexmedetomidine group compared to controls (1.3 vs 3.0 days; p=0.000).\n\n    Qiao 2022\n\n69\nInclude: Ages >65; ASA grade I or II; scheduled to undergo elective LLS.Exclude: A preoperative mini-mental state examination (MMSE) score less than or equal to 23; uncontrolled hypertension; uncontrolled diabetes; untreated cardiac disease; untreated pulmonary disease; hepatic failure; renal failure; epilepsy; current medications potentially affecting the central nervous system;  and preexisting mental status alterations.\n\nMMSE scored improved slightly in both groups compared to baseline during the early postoperative period. No differences were identified in MMSE scores between groups. Only three patients (9.6%) in the desflurane-based group and one patient (3.1%) in the propofol-based group developed cognitive impairment (p = 0.583).\n\n    Dieleman 2012\n\n4494\nInclude: Age > 18 yrs.Exclude: Emergent or off-pump procedure; life expectancy < 6 mo.\n\nPostoperative delirium was seen in 9.2% dexamethasone group and 11.7% in the placebo group (RR 0.79, 95% CI: 0.66-0.94, p=0.006).\nLarge multicenter clinical trial on dexamethasone. There were two substudies from this trial (Sauer 2014 and Ottens 2014) that focused on delirium and cognitive decline.\n    Celik 2011\n\n100\nInclude: Patients age 65-80; ASA physical status I-III; elective urological surgery lasting >1.5 hrs.Exclude: Routine use of sedative drugs; dialysis; emergency surgery; cardiac or repiratory failure.\n\nIn patients undergoing urologic surgery, patients receiving propofol had improved cognitive scores compared with patients receiving sevoflurane (p<0.05) at 30 minutes postoperation. Differences in cognition were not detected between the groups at 60 and 90 minutes postoperation.\n\n    de Jonghe 2014\n\n452\nInclude: Patients aged >= 65; acute admission for surgical repair of hip-fracture; enrolment within 24 hours of admission.Exclude: Transferred for surgical repair from another hospital; concomitant use of melatonin and prior participation in this study.\n\nDid not observe an effect of melatonin on the incidence of delirium, 55/186 (29.5%) in the melatonin group vs 49/192 (25.5%) in the placebo group; difference 4.1 (95% CI -0.05 to 13.1) percentage points. There were no between-group differences in mortality or in cognitive functional outcomes at 3-months follow-up.\n\n    Egawa 2016\n\n148\nInclude: Patients scheduled for elective lung surgery; age 20-85l ASA physical status I-III; fluency in Japanese; ability to read; absence of serious hearing or visual impairments that would preclude neuropsychological testing.Exclude: Patients with interstitial lung disease or lung fibrosis; pregnancy or possibility of pregnancy; history of neurological or mental illness; baseline MMSE score below 24; renal insufficiency (serum creatine in excess of 1.5 mg.dL-1); active liver disease (aspartate aminotransferase in excess of 40 U.dL-1); documented coagulopathy.\n\nRates of POCD did not differ statistically between groups five days postoperatively or three months postoperatively. Multivariable regression analysis revealed older age as an independent predictor of POCD.\n\n    Epple 2001\n\n124\nInclude: Patients age >65; ASA physical status I, II, III; scheduled for elective cataract surgery under general anesthesia.Exclude: Patients with a history of allergic reaction to one of the drugs used in the study.\n\nIn the propofol and remifentanil group, more patients were satisfied and would accept the same anesthetic again.\n\n    Ford 2020\n\n210\nInclude: Patients age >=50; elective cardiac surgery (coronary artery bypass graft or valve replacement).Exclude: Emergency surgery; contraindication to melatonin or already taking melatonin; dementia; Modified Telephone Interview for Cognitive Status score <=19; Alcohol Use Disorders Identification Test score >=15.\n\nIn patients undergoing cardiac surgery, a difference in postoperative delirium was not detected in patients receiving melatonin for 7 days (starting 2 days before surgery) compared with patients receiving placebo, 21/98 (21%) vs 21/104 (20%), adjusted OR (95% CI): 0.78 (0.35-1.75). Differences in delirium duration, delirium severity, cognitive function, anxiety and depression were also not detected between the groups.\n\n    Geng 2017\n\n150\nInclude: Patients age>=65; with ASA score II-III; sufficient level of education to be capable of completing neuropsychological tests.Exclude: Mini Mental State Examination score <=26; preexisting diagnosis of schizophrenia; preexisting diagnosis of dementia; known disorder affecting cognition; mental dysfunction; history of cerebral surgery; severe anxiety; recent history of alcohol abuse; history of chronic opioid or other psychotropic drug use; history of allergy to anesthetics; dialysis-dependent renal failure; liver transaminase level <1.5 times the normal value; recent stroke.\n\nThe incidence of POCD was lower in the propofol group compared to the isoflurane and sevoflurange group at postoperative day 1 (D1) and postoperative day 3 (D3) (propofol vs isoflurane: D1 and D3, P <0.001; propofol vs sevoflurane: D1, P = 0.012; D3, P = 0.013). The incidence of POCD was lower in the sevoflurane group compared to the isoflurane group at D1 (P = 0.041), but not at D3.\n\n    Luntz 2004\n\n96\nInclude: Patients age >=65; ASA physical status I-III; elective unilateral ophthalmic surgery.Exclude: Cardiovascular complaints (New York Heart Association III-IV); adverse reaction to study drug; general anesthesia in past 3 months; <60% vision in contralateral eye.\n\nIn patients undergoing opthalmic surgery, patients receiving sevoflurane alone reported less satisfaction with anesthesia induction compared with patients receiving propofol or propofol with sevoflurane (p<0.05). Differences in satisfaction with awakening and with anesthesia in general were not detected between the groups.\n\n    Partridge 2017\n\n201\nInclude: Age >= 65 years  scheduled for elective endovascular/open aortic aneurysm repair or lower-limb arterial bypass surgery.Exclude: Admitted directly to the ward from surgical clinic or emergency department.\n\nThere was a lower incidence of postoperative delirium (11% vs 24%, p=0.018), cardiac complications (8% vs 27%, p=0.001), and length of stay (3.32 vs 5.53 days, p<0.001) in patients receiving a CGA compared to standard preoperative care.\n\n    Prakanrattana 2007\n\n126\nInclude: Patients age >40; elective cardiac surgery with cardiopulmonary bypass.Exclude: Emergency surgery; patients admitted to ICU; tracheal intubation prior to operating room arrival; preoperative delirium; history of psychiatric problems.\n\nIn patients undergoing cardiac surgery requiring cardiopulmonary bypass, patients receiving sublingual risperidone postoperatively experienced less postoperative delirium compared with patients receiving placebo, 7/63 (11%) vs 20/63 (32%), RR (95% CI): 0.35 (0.16-0.77).\n\n    Prestmo 2015\n\n397\nInclude: Home-dwelling people aged 70 years or older who had been able to walk 10 m before the fracture were eligible.Exclude: Pathological fractures, multiple traumas, short life expectancy, or nursing home resident.\n\nMobility measured by SPPB index at 4 months postoperative was better in the CGA group compared to usual care with mean difference of 0.74 (95% CI: 0.18, 1.30; p=0.10).\n\n    Tang 2014\n\n220\nInclude: Memory complaints documented by the patient and a collateral informant; Montreal Cognitive Assessment test score 15-24; MMSE< 27; Activities of Daily Living score <22; no evidence of dementia.Exclude: Current diagnosis of dementia (preoperative MMSE score <23); current or past psychiatric illness; current use of antidepressant or antianxiety medication; history of drug dependence or alcohol abuse; history of coronary artery, peripheral arterial or cerebrovascular disease; severe visual, auditory, or motor handicap; acute infection; preoperative hemoglobin < 85 g/L.\n\nAt 7 days after surgery, the incidence of POCD was 29.7% in the propofol group and 33.3% in the sevoflurane group. Sevoflurane anesthesia had a more severe impact on cognitive function than propofol anesthesia.\n\n    Vidan 2005\n\n321\nInclude: Patients aged 65 years or older admitted for acute hip fracture surgery.Exclude: Inability to walk before fracture and dependency in all basic ADLs, pathological hip fracture, and know terminal illness.\n\nMedian length of stay was 16 days in the geriatric intervention group and 18 days in the usual care group (p=0.06). There was a lower mortality rate in the intervention group (0.6% vs 5.8%, p=0.03) and major medical complications (45.2% vs 61.7%, p=0.003).\n\n    Li 2021\n\n544\nInclude: Major elective gastrointestinal, gynecological, prostate, or bladder surgery patients who are >= 60 years old; laparoscopic surgery that is expected to last for >= 2hours under general anesthesia and the patient will be hospitalized for at least 7 days after surgery; lack of serious hearing and vision impairment.Exclude: Life expectancy less than 3 months; MMSE score <=23; history of dementia, psychiatric illness or any diseases of the central nervous system; current use of sedatives or antidepressants; alcoholism or drug dependence; patients previously included in this study; uncontrolled hypertension (>180/100mmHg).\n\n46 patients in the sevoflurane group and 38 patients in the propofol met the criteria for delayed neurocognitive recovery (OR:0.77, 95%CI: 0.48, 1.24). Anesthetic choice did not appear to affect the incidence of delayed neurocognitive recovery.\n\n    Mei 2018\n\n336\nInclude: Age >65 yrs; ASA I-IV.Exclude: Contradictions to lumbosacral plexus and T12 paravertebral block (ie coagulopathy, infection at puncture site, and refusal); patients with mental or language barriers; patients anesthetized within the past 30 days; severe congestive heart failure/severe chronic obstructive pulmonary disease; sinus sick syndrome; severe sinus bradycardia; second or greater atrioventricular block without pacemaker; cognitive impairment (MMSE <24)/preop delirium(CAM).\n\nThe patients sedated with dexmedetomidine had lower incidences of POD and POCD and were out of bed and discharged sooner than the patients sedated with propofol. There was no difference in complications between the two groups.\n\n    Shi 2019\n\n168\nInclude: >= 60 years of age; scheduled for cardiac surgery.Exclude: History of psychiatric diseases; inability to communicate; previous history of POD; diagnosed with preoperative sick sinus syndrome, severe bradycardia (heart rate ,50 beat per min), second-degree or above atrioventricular block without pace maker; diagnosed with severe hepatic or renal insufficiency.\n\nThere was no significance in incidence of POD between the dexmedetomidine group (n=33, 39.3%)\nand the propofol group (n=21, 26.3%, P=0.0758). The dexmedetomidine-treated\npatients also displayed a lower VAS score (30 vs 35, respectively; P=0.0309) and less opiate analgesic consumption (12 vs 21, respectively; P=0.0222) 24-h postop.\nNote that the registration number provided does not match with the current study.\n    Hudetz 2009\n\n78\nInclude: Patients age >=55; elective coronary artery bypass graft surgery and/or valve replacement/repair procedures with a cardiopulmonary bypass.Exclude: Cerebrovascular accident within 3 y; permanent ventricular pacing; previously documented cognifive deficits; hepatic impairment (aspartate aminotransferase or alanine aminotransferase greater than twice upper normal limit); chronic renal insufficiency (creatinine >2 mg/dL).\n\nIn patients undergoing surgeries requiring cardiopulmonary bypass, patients receiving ketamine experienced less of a decrease in cognitive performance (at least 2 standard deviations) compared with patients receiving a placebo, 7/26 (27%) vs 21/26 (81%), p<0.001 at 1 week postsurgery.\nTests used: Repeatable Battery for the Assessment of Neuropsychological Status subtests; Brief Visual Memory Test Revised; Backward Digit Span; Semantic Fluency; Phonemic Fluency\n    Zhang 2019\n\n464\nInclude: Patients age >=65; elective non-cardiac surgery under general anesthesia and admitted to ICU before 2000 h.Exclude: History of schizophrenia, epilepsy, Parkinsonism, myasthenia gravis; inability to communicate; brain injury or neurosurgery; left ventricular ejection fraction <30%; sick sinus syndrome; severe sinus bradycardia (<50 beats/min); secondary or greater atrioventricular block without pacemaker; serious hepatic dysfunction; low likelihood of survival >24 h.\n\nA followup study of 700 patients randomized to postsurgical dexmedetomidine vs saline reported the dexmedetomidine group experienced higher survival rates (95% CI) at 1 y compared with the saline group, 87.7 (84.2-91.2) vs 82.4 (78.5-86.3), rate difference=5.3 (0.0-10.6), p=0.049.\nAmong study participants surviving 3 y (N=434), patients receiving dexmedetomidine experienced better cognitive function (mean difference 4.7, 95% CI 3.8-5.6, p<0.0001) and better quality of life (physical, psychological, social, environmental domains) compared with patients receiving placebo.\n    Gao 2020\n\n60\nInclude: Age 65-75; ASA II-III; NYHA grade II-III; Body Weight 55-85 kg;.Exclude: Mental illness; Previous acute myocardial infarction; previous diagnosis of heart failure; diabetes; brain trauma; cerebrovascular accident; left ventricular ejection fraction >40%; abnormal liver and kidney function; sedatives or antidepressants intake; history of drug abuse; sick sinus syndrome;.\n\nAt 72 h and 7d after operation, incidence of cognitive dysfunction in the dexmedetomidine group was lower compared with the placebo group (P <0.05).\n\n    Hudetz 2009\n\n58\nInclude: Patients age >=55; elective coronary artery bypass graft surgery and/or valve replacement/repair procedures with a cardiopulmonary bypass.Exclude: Cerebrovascular accident within 3 y; permanent ventricular pacing; previously documented cognifive deficits; hepatic impairment (aspartate aminotransferase or alanine aminotransferase greater than twice upper normal limit); chronic renal insufficiency (creatinine >2 mg/dL); increased risk of perioperative complications; use of psychoactive drugs for psychosis.\n\nIn patients undergoing surgeries requiring cardiopulmonary bypass, patients receiving ketamine experienced less postoperative delirium compared with patients receiving a placebo, 1/29 (3%) vs 9/29 (31%) within 5 days postsurgery, p=0.01.\nDelirium defined as ICDSC >=4.\n    Xin 2021\n\n60\nInclude: >65; laparoscopic cholecystectomy; patients with mild cognitive impairment (MoCA 15-24, MMSE <27, CDR 0.5, daily living score <26).Exclude: Preoperative delirium; preop neurological diseases affecting cognitive function; severe liver and renal insufficiency; autoimmune diseases; recent use of sedatives; antidepressants or immunosuppressive drugs; traumatic brain injury; history of alcoholism.\n\nPOD occurred in 10/30 patients in the control group, and 3/30 patients in the dexmedetomidine group. Dex can alleviate POD in elderly patients with MCI.\n\n    Hollinger 2021\n\n200\nInclude: Aged ≥65 years and scheduled for visceral, orthopaedic, vascular, gynaecological, cardiac, or thoracic surgery.Exclude: Delirium at admission; MMSE score < 24; DOS >= 3; dementia; known ICU admission; haloperidol or ketamine intolerance; communication issues; QT interval prolongation; Parkinson's disease; epilepsy; body weight > 100 kg; intake of dopaminergic drugs.\n\nDelirium was seen in 6.4% of patients in the ketamine group, 11.1% with haloperidol, and 9.1 % with placebo (p=0.16).\nBaden PRIDe Trial was an investigator-initiated, phase IV, two-centre, randomised, placebo-controlled, double-blind clinical trial. The purpose of this study was to identify within a cohort of ICU patients admitted for severe illness those who are at risk of death in the year following the discharge from ICU. Eleven other articles have indexed this trial.\n    Deiner 2017\n\n429\nInclude: >68; major elective noncardiac surgery.Exclude: MMSE <20; dementia; emergency surgery; intracardiac or intracranial surgery; planned postop intubation; severe visual or auditory handicap; illiteracy; parkinsons disease; life expectancy <6months; renal failure requiring dialysis; sick sinus syndrome; second or third-degree heart block or clinically significant sinus bradycardia; contraindication for use of an a2-adrenic agonist; ASA class IV or V; hepatic dysfunction.\n\nNo difference in postop delirium delirium between the dexmedetomidine and placebo groups. After adjusting for age and education, there was no difference in postop cognitive performance between treatment groups at 3 and 6 months. Adverse events were comparably distributed between the two groups.\nThe study was stopped for futility in accord with the DSMB in January 2014 based on a planned interim analysis in the spring of 2013. The conditional power for concluding efficacy under the original assumption of treatment effect was 3% and under the observed trend and a null trend was less than 1% for both. The conditional power for concluding harm was less than 25% under the 3 different assumptions.\n    Momeni 2021\n\n420\nInclude: Patients age >=60; cardiac surgery with cardiopulmonary bypass.Exclude: Hepatic dysfunction (liver enzyme 3x upper normal limit with serum albumin below normal limit); preop delirium; surgery without cardiopulmonary bypass; emergency surgery; chronic renal replacement therapy.\n\nIn patients undergoing cardiac surgery with cardiopulmonary bypass, a difference was not detected in postoperative delirium during the hospital stay, among patients receiving postoperative dexmedetomidine vs saline, 31/177 (18%) and 33/172 (19%), p=0.69. Patients receiving dexmedetomidine experienced shorter duration of delirium compared with patients receiving saline, p=0.026.\n\n    Rascon-Martinez 2016\n\n80\nInclude: Patients age >=60; ASA I-III; vitrectomy or cataract surgery involving retrobulbar block.Exclude: History of psychosis, schizophrenia, nephropathy; difficult to control arterial blood pressure; uncontrolled hepatic disorders; ketamine allergy; moderate to severe depression; postop depression; required medications other than study drugs.\n\nIn patients undergoing opthalmic surgeries, more patients receiving ketamine during surgery experienced improved cognitive scores 2 h postsurgery compared with patients receiving a placebo, mean change in error score of -1.0 (1.1) vs -0.2 (0.9), p=0.001.\nShort Portable Mental Status Questionnaire used, with change in error scores reported (negative change in error score would indicate improvement).\n    Djainai 2016\n\n185\nInclude: Age >60 undergoing elective complex cardiac surgery; AND age >70 undergoing either isolated coronary revascularization or single-valve repair/replacement surgery with the use of cardiopulmonary bypass (CPB).Exclude: Hx of serious mental illness; hx of delirium; hx of severe dementia; currently undergoing emergency procedures.\n\nPOD was present in 16 of 91 (17.5%) and 29 of 92 (31.5%) of patients in dexmedetomidine and propofol groups, respectively (odds ratio, 0.46; 95% CI, 0.23 to 0.92; P= 0.028). Duration of POD 2 days (1 to 4 days) versus 3 days (1 to 5 days), P=0.04, in dexmedetomidine and propofol groups, respectively.  The absolute risk reduction for POD was 14% with a number needed to treat of 7.1.\n\n    Sun 2019\n\n618\nInclude: Age >65; ASA I to III; scheduled to undergo major elective noncardiac surgery under general anesthesia without a planned ICU stay; MMSE >=20; agree to use of patient-controlled intravenous analgesia pump.Exclude: Hx of schizophrenia; hx of epilepsy; emergency surgery; intracardiac surgery; intracranial surgery; sick sinus syndrome; clinically significant sinus bradycardia; second-degree or higher heart block in the absence of a pacemaker; serious liver dysfunction (Child-Pugh class C); serious kidney failure (requiring dialysis); hx of Parkinson's disease; hx of myasthenia gravis; allergy to alpha2-adrenergic agonist; allergy to opioids; prior recruitment in other clinical trials.\n\nThe incidence of POD had no difference between he dexmedetomidine and placebo groups (11.7% [33 of 281] vs 13.8% [38 of 276], P=0.47).\n\n    Su 2016\n\n700\nInclude: Patients age >=65; elective non-cardiac surgery under general anesthesia and admitted to ICU before 2000 h.Exclude: History of schizophrenia, epilepsy, Parkinsonism, myasthenia gravis; inability to communicate; brain injury or neurosurgery; left ventricular ejection fraction <30%; sick sinus syndrome; severe sinus bradycardia (<50 beats/min); secondary or greater atrioventricular block without pacemaker; serious hepatic dysfunction; low likelihood of survival >24 h.\n\nIn non-cardiac surgery patients, those receiving dexmedetomidine intravenously from ICU admission until 0800 h postop day 1, experienced less postop delirium compared with patients receiving saline, 32/350 (9%) vs 79/350 (23%), OR (95% CI): 0.35 (0.22-0.54), p<00001.\n\n    Shehabi 2009\n\n306\nInclude: Patients age >=60 years; undergoing pump cardiac surgery.Exclude: Allergy to study drugs; using other alpha2 agonists (clonidine or psychoactive agents other than night time hypnotics); heart rate <55 beats/min and/or systolic bp <90 mmHg; weight >150 kg; preop creatinine >1.6 mg/dL or creatinine clearance <50 ml/min; preop dementia, Parkinson disease, recent seizures.\n\nIn patients undergoing cardiac surgery, a difference was not detected in postoperative delirium in patients receiving dexmedetomidine versus morphine postoperatively, 13 (9%) vs 22 (15.%), risk ratio (95% CI): 0.57 (0.26-1.10), p=0.09. However, patients receiving dexmedetomidine experienced shorter delirium duration, 2 (IQR, 1-7) vs 5 (IQR, 2-12) days, p=0.03.\nIn small subgrp of patients requiring intraaortic balloon pump, patients receiving dexmedetomidine experienced less postoperative delirium compared with patients receiving morphine, 3/20 (15%) vs 9/25 (36%), RR 0.42 (95% CI, 0.15-0.64).\n    Yang 2017\n\n285\nInclude: Age >=60; scheduled to undergo elective coronary artery bypass graft and/or valve replacement surgery.Exclude: History of schizophrenia; history of epilepsy; diagnosis of Parkinson disease; diagnosis of severe dementia; inability to communicate because of severe visual/auditory dysfunction or language barrier; history of functional neurosurgery or brain injury; diagnosis of preoperative sick sinus syndrome; diagnosis of severe bradycardia (heart rate <50); diagnosis of second-degree or above atrioventricular block without pacemaker; diagnosis of severe hepatic insufficiency (Child-Pugh grades C); diagnosis of severe renal insufficiency (requirement of renal replacement therapy); patient refused to participate in the study.\n\nDexmedetomidine administered during anesthesia and early postoperative period did not decrease the incidence of delirium (4.9% [7/142] in the DEX group vs 7.7% [11/143] in the CTRL group; OR 0.62, 95% CI 0.23 to 1.65, p = 0.341) in elderly patients undergoing elective cardiac surgery.\n\n    Lee 2015\n\n56\nInclude: Age >60; ASA I-III; undergoing orthopedic surgery (duration of anesthesia > 2 hours).Exclude: Dementia; Hx of CNS-related diseases; medication with tranquilizers; medication with antidepressants; inability to perform neurocognitive function tests; severe visual or auditory dysfunction; hx of alcohol abuse; hx of drug dependence; hx of a cerebrovascular accident within the previous 3 years.\n\nThere was a difference between the trail-making test scores in which the saline group had increased scores than the ketamine group at POD 1 (52.5 vs 13 points, respectively; p=0.047). There was no difference detected in the mini-mental status examination at either POD 1 (p=0.98) or POD 6 (p=0.33) and the digit substitution test at either POD 1 (p=0.39) or POD 6 (p=0.81). There was no difference in the MMSE (p=0.19), trail making test (p=0.08) and digit substitution test socres (p=0.28) between the two groups throughut the time.\n\n    Lee 2018\n\n354\nInclude: Age >65 years; ASA I-III; scheduled for laparoscopic major non-cardiac surgery under general anesthesia.Exclude: History of kidney or liver disease; allergy to the drug; cognitive impairment; use of antipsychotic alpha-2 agonists or antagonist meds; use of anti-inflammatory drugs.\n\nDexmedetomidine group 1 (1 ug/kg bolus followed by 0.2-0.7 ug/kg infusion) reduced incidence and duration of delirium compared to control (9.5% vs 24.8%, p=0.017). Dexmedetomidine group 2 (1 ug/kg bolus only) decreased its duration in patients with delirium compared to control (18.4% vs 24.8%). Dose and timing of dexmedetomidine appeared to be important in preventing delirium.\n\n    Subramaniam 2019\n\n140\nInclude: >60 year; coronary artery bypass graft surgery with or without aortic and/or mitral value replacement.Exclude: Preoperative left ventricular ejection fraction of less than 30%; preexisting cognitive impairment; alzheimer disease; parkinson disease; medications for cognitive decline; history of recent seizures; serum creatine levels above 2ml/dL; liver dysfunction; recent history of alcohol misuse; hypersensitivity to study medications.\n\nNA\n4 arms: dex-placebo, propofol-placebo, dex-acetaminophen, propofol-acetaminophen \nonly extracted placebo arms as of now.\n    Lee 2018\n\n132\nInclude: Patients age 18-75 years; ASA physical class I-II; elective TKA or THA under spinal anesthesia.Exclude: Allergy and/or contraindication to study drugs; clinically significant medical or psychiatric conditions; pregnancy; alcohol or drug abuse; use of opioids and/or study drugs for chronic pain; significant cardiac, hepatic, or renal disease.\n\nIn patients undergoing TKA or THA, patients receiving dexmedetomidine experienced less postoperative delirium compared with patients receiving placebo or pregabalin, 3/31 (9.7%) vs 11/31 (35.5%) or 14/33 (42.4%), p<0.05. A difference was not detected in postoperative delirium in patients receiving dexmedetomidine compared with patients receiving pregabalin plus dexmedetomidine.\nDexmedetomidine was more effective than pregablin for clinically relevant pain. Differences were not detected in pain or morphine use in patients receiving dexmedetomidine compared with patients receiving pregabalin plus dexmedetomidine.\n    Glumac 2017\n\n169\nInclude: Patients age 41-84 years; elective coronary artery bypass graft, heart valve, or combined surgery with or without cardiopulmonary bypass.Exclude: Cerebrovascular incident past 3 yrs; mental illness; visual, hearing, or motor impairment interfering with cognitive assessment; left ventricular ejection fraction <35%; adrenal gland disease requiring steroids >7 days in past yr; alcohol (>50 g/day or >500 g/wk) or substance abuse; MMSE <26; BDI-II >19; preop CRP >5 mg/L; preop WBC <4 or >10 x10(ninth)/L; stroke; additional corticosteroid during study period.\n\nPatients undergoing cardiac surgery who received dexamethasone (n=80) experienced less postoperative cognitive decline compared with patients who received placebo (n=81), RR (95% CI): 0.43 (0.21-0.89). Subgroup analysis by age shows patients >=65 experience less cognitive decline when receiving dexamethasone (RR, 95% CI: 0.22, 0.05-0.94), while no difference is detected among patients <65 (RR, 95% CI: 0.59, 0.26-1.36).\n\n    Rohan 2005\n\n45\nInclude: Age above 65; presenting for urological and gynecological surgery; requiring general anesthesia; anticipated hospital stay of on night postoperatively;.Exclude: Diseases of the central nervous system including pre-existing cognitive dysfunction; consumption of phenothiazines or antidepressants; cardiac or neurosurgery; previous neuropsychological testing; poor comprehension of the language used in processing the study tests; patients with alcoholism or addictive drug dependence.\n\nIncidence of post-operative cognitive dysfunction (POCD) in elderly patients on the first day after minor surgery is higher than previously reported for seven days after major surgery, and is increased after both Propofol and sevoflurane anesthesia, compared with age-matched controls.\n\n    Tanaka 2017\n\n100\nInclude: Age >65 years old; BMI >30kg/m2; undergoing primary knee arthroplasty surgery; ASA class II-III.Exclude: Failure of regional block; preexisting neurocognitive disorders.\n\nFound a low incidence of delirium, but significant cognitive decline in the first 48 hours after surgery.  There was no difference in the incidence of postoperative delirium between the two groups.\n\n    Avidan 2017\n\n746\nInclude: Age >60; undergoing major open cardiac; undergoing non-cardiac surgeries; under general anaesthesia.Exclude: Dx of delirium prior to surgery; allergy to ketamine; those for whom a significant elevation of blood pressure would constitute a serious hazard; hx of drug misuse; pts currently taking anti-psychotic medications; pts with a weight outside the range of 50 kg - 200 kg.\n\nThere was no difference in postoperative delirium incidence between those in the combined ketamine groups and those who received the placebo (19.45% vs 19.82%, respectively; absolute difference, 0.36%; 95% CI, -6.07% to 7.38%, p=0.92).\n\n    Hu 2021\n\n177\nInclude: Patients age 60-80 years; ASA status I-III; open transthoracic oesophagectomy under general endotracheal anesthesia.Exclude: BMI >30 kg/m2; severe pulmonary, cardiac, renal, hepatic, cerebrovascular comorbidities; chronic pain or substance abuse; dementia or treatment with antipsychotic drugs; dexmedetomidine allergy; life expectancy <6 months.\n\nIn patients undergoing open transthoracic oesophagectomy under general endotracheal anesthesia, patients receiving dexmedetomidine experienced less postoperative delirium compared with patients receiving saline, 15/90 (16.7%) vs 32/87 (36.8%), p=0.0036.\n\n    Lu 2017\n\n152\nInclude: Patients age >=60 years; ASA status II-III; elective shoulder arthroscopy.Exclude: History of neurological or psychiatric disorders; psychotropic drugs; alcohol or drug dependence; use of pain medications; use of opioid or dexmedetomidine for allergies; MMSE <23; COPD; history of heart block or sinus bradycardia.\n\nIn patients undergoing shoulder arthroscopy, patients receiving sufentanil and dexmedetomidine postoperatively experienced higher MMSE scores compared with patients receiving sufentanil alone on day 1 (p=0.003), day 2 (p=0.002), and day 7 (p=0.001) following surgery.\n\n    Royse 2017\n\n555\nInclude: Enrolled in SIRS (Whitlock 2015): age >=18 years; EuroSCORE >=6; cardiac surgery requiring cardiopulmonary bypass.Exclude: Known cognitive impairment or psychiatric illness; (from Whitlock 2015: taking or expected to take steroids immediately postop; bacterial or fungal infection preceding 30 days; steroid intolerance or allergy; expected to receive aprotonin).\n\nIn a substudy of patients undergoing cardiac surgery requiring cardiopulmonary bypass, a difference was not detected in overall recovery at 6 months in patients receiving methylprednisolone compared with patients receiving placebo, odds ratios over time 039 to 1.45 (95% CI, 0.08-2.04 to 0.40-5.27). Differences were not detected in the subcategories of the recovery scale (cognitive, anxiety and depression, activities of daily living) between the study groups.\n\n    Zhang 2018\n\n120\nInclude: 65-75; underwent esophageal carcinoma; level of education that is capable of completing the neuropsychological teats; preop MMSE score >=23; no central nervous system lesions; no tranquilizers or antidepressants; no history of cardiovascular or respiratory disease; no history of alcohol or cigarette abuse or drug dependence; no obvious or abnormal renal or hepatic functions; no serious hearing or vision impairments; no anaphylactic reactions to anesthetics.Exclude: <65, >75; see inclusion.\n\nCompared with Group M+S, the MMSE and MoCA scores were significantly higher in group D+S at the 1st, 3rd, and 7th postoperative days.\n\n    van Norden 2021\n\n63\nInclude: Age >60 yrs; major elective cardiac or major abdominal surgery.Exclude: Known drug intolerance or allergy to dexmedetomidine; unable to provide written consent; history of major neurocognitive disorder (MMSE< 24); severe audiovisual impairment; traumatic brain injury; intracranial bleeding < 1 y before the inclusion date; psychiatric illness; history of alcohol or drug abuse; pregnancy; haemodynamic dysfunction (severe hypotension, defined as a mean arterial pressure < 55 mmHg despite optimal preload and vasopressor therapy); second- or third-degree atrioventricular heart block; severe sinus bradycardia (< 50 bpm at rest); spinal injury with autonomic dysfunction; pre-operative cerebrovascular accident with residual neurological deficit; Child C liver cirrhosis; intra-operative use of remifentanil or clonidine; additional administration of dexmedetomidine within 3 months after inclusion; and planned postoperative deep sedation Richmond Agitation Sedation Scale (RASS) < 4.\n\nDexmedetomidine was associated with a reduced incidence of postop delirium within the first 5 preop days compared to placebo, 43.8% vs. 17.9%, p = 0.038.\n\n    Shi 2020\n\n106\nInclude: MMSE >24; >=65; male; scheduled for thoracoscopic lobectomy with OLV; expected surgery time between 2 and 4 hr; general anesthesia.Exclude: Not allowed to smoke for at least 14 days prior; systolic bp >= 180 or <90 mmHg; diastolic bp >=110 or <60 mmHg; serious heart, liver, kidney, lung, endocrine, nervous system, or severe infection; administration of sedatives or antidepressants; abnormal results of preop MMSE, MoCA, or CAM; contradictions regarding epidural anesthesia, epidural puncture failure; severe vision disorder; allergies to study drugs; sleep disorders; history of: perioperative severe cardiovascular disease, respiratory complications, inability to complete thoracoscopic lobectomy incompatibility with the neurologic scale assessments and other unpredictable adverse events.\n\nAt 6 h and on the first day postoperatively, the MoCA score in the DEX group was significantly higher than that in the saline group. The incidence of POCD and POD in the DEX group was 13.2 and 7.5%, respectively, while that in the saline group\nwas 35.8 and 11.3%, respectively. There was a significant difference in the incidence of POCD between the two groups (P<0.01). In the DEX group, mean sleep quality was increased, whereas the mean VAS was decreased compared with the corresponding values in the saline group. In conclusion, elderly male patients who underwent thoracoscopic lobectomy under continuous infusion of DEX exhibited a reduced incidence of POCD during the first 7 postoperative days as compared with the placebo group.\nonly male ??\n    Zhao 2020\n\n432\nInclude: Age > 65; ASA I-III; scheduled to undergo non-cardiac major surgery.Exclude: MMSE scores of less than 17 in illiterate (uneducated) patients; MMSE score less than 20 for pts with elementary education (education of <=6 years); MMSE scores less than 24 for patients with secondary education or higher (education > 6 years);  inability to communicate during the preoperative period (owing to coma, profound dementia, or a language barrier); regular use of opioids; use of sedatives; use of antidepressants; use of anxiolytic drugs; hx of drug addiction; severe visual or hearing disorders; preoperative hx of schizophrenia; hx of epilepsy; hx of Parkinsons; Hx of myathenia gravis; brain injury; hx of neurosurgery; serious hepatic dysfunction (Child-Pugh class C); serious renal dysfunction (undergoing dialysis before surgery); a preoperative left ventricular ejection fraction less than 50%; sick sinus syndrome; severe sinus bradycardia (<50/min); second degree or greater atrioventricular block without a pacemaker; allergy to sufentanil; allergy to dexmedetomidine.\n\nThe overall incidence rates of POD and early POCD 7 days after surgery were lower in the dexmedetomidine 200 mcg and 400 mcg groups than in the dexmedetomidine 0 mcg and 100 mcg groups (p <0.05). Compared with dexmedetomidine 200 mcg, dexmedetomidine 400 mcg reduced early POCD in patients who underwent open surgery (P >0.05).\n\n    Zangrillo 2011\n\n153\nInclude: Over age of 18; signed written informed consent; planned for general anesthesia;.Exclude: Previous unusual response to anesthetic use of sulfonylurea, theophylline, or allopurinol;.\n\nPatients undergoing noncardiac surgery did not benefit from using volatile agents (sevoflurane) compared to TIVA.\n\n    Nishikawa 2004\n\n50\nInclude: Patients in ASA class I or II; age >65; scheduled for elective laparoscope-assisted surgical procedures which would last more than 3 hours under combined general and epidural anesthesia.Exclude: Patients with anticoagulation; symptomatic coronary artery disease; cardiac valvular regurgitation or stenosis; central nervous system or neuromuscular disorders; major or minor tranquilizer medication; psychotic symptoms; and neurocognitive impairment as judged by a psychiatrist were excluded.\n\nThere was no significant difference between the incidences of POD in the two groups during the first 3 days after surgery. The scored for DRS on day 2 and 3 after surgery, however, were significantly higher in group propofol than in group servoflurane (p<0.01).\nNo registration, dates, funding, or COI info included. Searched all 3 databases by title but could not find the study on any registration site.\n    Weaver 2003\n\n136\nInclude: Medicare eligible; lived within geographic catchment area; scheduled for THR or TKR.Exclude:  Not specified.\n\nThere were no differences between the treatment and control groups in functional status (Barthel score; 96.7 vs 96.6, p=0.940), 8 health-related quality of life, or lower extremity functioning (WOMAC index; 4.2 vs 4.2, p=0.789) by group at 1 follow-up.\n\n    Qiao 2015\n\n90\nInclude: Patients in ASA status I, II, or III; preoperative MMSE score >=23; no evidence of cardiovascular, respiratory or central nervous system disease; normal renal and hepatic function; no serious hearing or visual impairment; absence of a history of benzodiazepine or antidepressant use, alcohol or cigarette misuse or drug dependence.Exclude: Alzheimer's disease; a family history of mental illness or mental illness; a cognitive impairment of the disease; a history of alcohol and drug dependence.\n\nThe MMSE and MoCA scored were significantly lower in the sevoflurane group than in the propofol control group on the first, third, and seventh postoperative days (p<0.05).\nOnly abstracted propofol vs sevoflurane, the article provided a separate p-value\n    Lindholm 2013\n\n231\nInclude: Patients who were scheduled for open, elective abdominal aortic aneurysm surgery; ASA class I-IV.Exclude: Patients <18 years old; included in other pharmaceutical studies; history of opioids, bensodiazepins, antiepileptic drugs, alcohol, and a2-agonist abuse; pregnant and breastfeeding women; family history of malignant hyperthermia; hypersensitivity to opioids, propofol or volatile anesthetics; considerable arrhythmia; uncontrolled hypertension, or serious psychiatric disease; unstable angina pectoris or myocardial infarction last month before inclusion; acute abdominal aortic surgery; acute dissection or rupture; planned laparoscopic abdominal aortic aneurysm surgery.\n\nAlthough underpowered, the authors found no differences in postoperative complications, nonfatal coronary events, or mortality between groups.\n\n    Ding 2015\n\n40\nInclude: Age 45-80 yrs; ASA I-III; BMI 18-25 kg/m2;.Exclude: Cardiovascular disease; hepatic or renal dysfunction; COPD; endocrine and metabolic disease; CNS disease; acute upepr respiratory infection.\n\nPOCD was seen in 15% of patients in the dexmedetomidine group compared to 35% in the control group 1 day after surgery, and 5% vs 20% 5 days after surgery respectively.\n\n    Hakim 2012\n\n101\nInclude: Age > 65 yrs.Exclude: Hx of neuropsychiatric disorders, alcoholism; intake of psychotropic mediations.\n\nIncidence of postoperative delirium was lower in the risperidone group compared to placebo (13.7% vs 34%, p=0.031) when given post-operatively.\n\n    Li 2021\n\n20\nInclude: Age 65-90 yrs.Exclude: MMSE < 24; mental and neurological disease; hepatic or renal disease; bradycardia or hypotension.\n\nIncidence of POCD was 40% in the control group and 6.7% in patients given highest dose of dexmedetomidine.\nThree doses of dexmedetomidine compared to placebo to determine occurrence of POCD.\n    Li 2015\n\n100\nInclude: ASA I-III; age >60 yrs;.Exclude: Age > 75 yrs; stroke; stupor; dementia; hepatic or renal dysfunction; bradycardia; hypotension.\n\nModerate cognitive impairment (MMSE 9-21) 24 hour after surgery was seen in 2% patients in dexmedetomidine group and 4% in the control group. No patients developed severe cognitive impairment (MMSE <9) 24 hour surgery.\n\n    Zhang 2020\n\n240\nInclude: Age 65-90 yrs; ASA I-III.Exclude: Hx psychosis, long-term use of psychotropic medication; alcohol abuse; MMSE <=23; illiterate; stroke; TIA; communication barriers.\n\nDexmedetomidine decreased POD incidence on first day after surgery compared to placebo (18.2 vs. 30.6%, P = 0.033).\n\n    Sultan 2010\n\n222\nInclude: Age > 65 yrs; ASA I-III.Exclude: Dementia; alcohol abuse; blind/deaf; severe infection; severe anemia; stroke; fluid or electrolyte imbalance; acute cardiac event; acute pulmonary events; on anticonvulsants, antidepressants, antihistamines, antiparkinsonians, antipsychotics, benzodiazepines.\n\nPostoperative delirium was seen in 9.4% of patients given melatonin compared to 32.6% in the control group. This study also compared patients given midazolam (44%) and clonidine (37.2%) preoperatively.\n\n    Siripoonyothai 2021\n\n75\nInclude: Age >65 yrs; Euroscore <4.Exclude: Dementia; cognitive impairment; psychiatric or mental disorder; positive on CAM; cerebrovascular disease; carotid disease;.\n\nPostoperative delirium was detected in 31% of patients in the ketamine group and 56% in the Propofol group.\n\n    Hong 2021\n\n712\nInclude: Age 65-90 yrs; ASA I-III.Exclude: Hx of schizophrenia, epilepsy, parkinsons, or myasthenia gravis; dementia; sick sinus syndrome, severe bradycardia; sleep apnea; hepatic dysfuncion; renal failure;.\n\nThe incidence of postoperative delirium was 7.3% with placebo and 4.8% with dexmedetomidine (RR 0.65, 95% CI 0.36 to 1.18; p=0.151).\n\n    Chawdhary 2020\n\n87\nInclude: Age >=55 yrs; ASA I-III.Exclude: MMSE <=23; any cognitive impairment; substance abuse; cardiac co-morbidity; stroke or seizures.\n\nPOCD on postoperative day 3 in the dexmedetomidine group was 32.5% compared to the propofol group 22.5% (p=0.31).\n\n    Gao 2021\n\n40\nInclude: Age 65-77 yrs; ASA II-III; weight 56-75 kg; HYHA II-III;.Exclude: Dementia and mental history; cerebrovascular disease; acid-base imbalance; electrolyte disturbance; abnormal liver and kidney function; MI; brain trauma; diabetes.\n\nThe incidence of postoperative cognitive dysfunction (POCD) in the Dexmedetomidine group was significantly lower than that in the control group at postoperative 7 days and postoperative 30 days (10% vs 40%; 0% vs 20%, p < .05).\n\n    Cai 2012\n\n2216\nInclude: Patients undergoing surgery in the Second Affiliated Hospital.Exclude: Requiring post-operative intensive care; post-operative sedation; did not consent to the study; severe lung disease or hepatic or renal dysfunction;.\n\nMMSE score in inhalation group was lower at day 3 after surgery compared with the intravenous anesthesia group (mean score 20.8 vs 26.9, p<0.01).\n\n    Chen 2013\n\n126\nInclude: Age 60-75 yrs.Exclude: Hx of mental illness; hypotension; bradycardia; CNS disease.\n\nSevere cognitive impairment was not seen in either dexmedetomidine or control groups 24 hour after surgery. Moderate cognitive impairment was seen in 1.7% of patients in the dexmedetomidine group and 3.2% in the control (p=0.598). In patients older than 65 years, mean MMSE was 27.9+-1.3 in the dexmedetomidine group and 28.2+-0.9 in the control group one month after surgery.\n\n    Guo 2015\n\n184\nInclude: Age 65-80 yrs; ASA I-III;.Exclude: Dementia or MMSE < 24; hx of CNS injury; hypotension; endocrine/metabolic disorders; inflammatory diseases; alcohol or drug dependence;.\n\nMean MMSE on postoperative day 3 was higher in the dexmedetomidine group compared to placebo (27.1 +- 2.0 vs 25.8 +- 2.7, p=0.001). Quality of recovery score was higher in the dexmedetomidine group compared to placebo in all three postoperative days compared to placebo (Day 1: 146.8 +- 24.2 vs 129.5 +- 22.5; Day 2: 155.3 +- 26.4 vs 136.9 +- 21.1; Day 3: 163.1 +- 25.3 vs 145.6 +- 28.6, p<0.001).\n\n    Zhang 2021\n\n174\nInclude: Age 18-79 yrs; ASA I-III.Exclude: Dementia; psychosis; cerebrovascular disease; acid-base imbalance, electrolyte imbalance; diabetes.\n\nIncidence of POCD was calculated in both dexmedetomidine and control groups as 9.20% and 21.31% (p=0.038), respectively.\n\n    Ommundsen 2018\n\n122\nInclude: Patients age >65; meeting one or more frailty criteria - 1) Vulnerable Elders Survey score >2, 2) severe comorbidity (eg, heart failure, COPD, renal failure), 3) cognitive impairment (eg, dementia), 4) malnutrition (BMI <20 kg/m2 or weight loss >5% last 6 months), and 5) polypharmacy (>5 daily medications); elective resection of adenocarcinoma in colon and/or rectum.Exclude: Emergency surgery.\n\nIn frail patients undergoing resection of adenocarcinoma in colon or rectum, differences were not detected in patients receiving tailored interventions based on preoperative geriatric assessments compared with patients receiving usual care in Grade II-V complications (68% vs 75%, p=0.43), reoperation (19% vs 11%, p=0.24), length of stay (8 days both groups), readmission (16% vs 6%, p-0.12), or 30 day survival (4% vs 5%, p=0.79).\nA model including study group, Vulnerable Elders Survey score, and TNM stage showed patients receiving tailored interventions experienced fewer Grade I-V complications compared with the control patients, OR=0.33 (95% CI, 0.11-0.95).\n    Zhu 2018\n\n178\nInclude: Patients age 65-75 years; elective total knee arthroplasty under general anesthesia.Exclude: MMSE <23; peptic ulcer disease; cardiac-cerebral vascular disease; chronic obstructive pulmonary disease; neurological or psychiatric disorders; NSAIDS allergy; drug or alcohol abuse; hepatic and/or kidney dysfunction; BMI >35; inability to communicate.\n\nIn patients undergoing total knee arthroplasty, at 7 days follow-up, 10/81 (12.3%) patients receiving celecoxib (200 mg, twice daily, 7 days preop) experienced postoperative cognitive dysfunction compared with 28/82 (34.1%) patients receiving placebo.\n\n    Zhou 2019\n\n180\nInclude: Patients age >70 years; ASA status I-II; hip arthroplasty surgery.Exclude: History of gastric ulcer or duodenal ulcer; flurbiprofen allergy; severe hepatic or renal disorders; ischemic heart disease; general or local infections.\n\nAmong patients undergoing hip arthroplasty surgery, patients receiving 50 mg flurbiprofen preoperatively (n=60) experienced higher MMSE scores compared with patients receiving nothing (n=60, p<0.01) and patients receiving 50 mg flurbiprofen intraoperatively (n=60, p<0.05) at 3, 12, and 24 h postsurgery. Patients receiving flurbiprofen intraoperatively experienced higher MMSE scores compared to patients receiving nothing, p<0.05.\n\n    Jellish 2003\n\n60\nInclude: Isolated unilateral endarterectomies by the same surgeon.Exclude: Patients undergoing emergency procedures; atrial fibrillation; significant renal or hepatic disease.\n\nPostoperative variables were similar except that patients who received iso/fen had lower Stewart recovery scores during the first 15 minutes after post anesthesia care unit admission and a higher incidence of nausea and vomiting the day after surgery, whereas patients receiving remi/prop had discharge delays secondary to hypertension. ICU admittance, time to first void, oral intake, and time to hospital discharge were similar between the groups.\nNo COI, funding, or registration number reported. No age criteria\n    Fan 2017\n\n148\nInclude: Age > 65 yrs; ASA I-III.Exclude: MMSE < 23; allergy to melatonin; chronic sleep disorder; alcoholism; drug abuse; psychiatric or neurological diseases.\n\nMMSE score in the melatonin group remained unchanged during the 7 days of postoperative monitoring compared to control group (p <0.05).\n\n    Dai 2021\n\n164\nInclude: Patients had a known diagnosis of CAD confirmed by prior AMI or coronary angiography, or the occurrence of representative angina pectoris, and at least 2 of the following risk factors: age >65, active smoking, hypertension, hyperlipidemia, and diabetes mellitus; patient was scheduled for major noncardiac surgery; percutaneous coronary intervention within 2 months.Exclude: Signs of acute cardiac failure; unstable angina; recent onset (< 6 months) myocardial infarction; percutaneous coronary intervention within 2 months; emergency surgery; combined or repeated procedures; participation in other research that might interfere with the current study endpoint.\n\nOccurrence of delirium did not differ between the sevoflurane and propofol groups.\n\n    Sun 2022\n\n80\nInclude: Age >65 yrs; ASA II-III; BMI < 28 kg/m2; radical cancer surgery.Exclude: Mental illness; hypertension; hypotension; cardiac disease; brain disease; lung disease; endocrine disease; difficult airway; alcohol abuse; neuromuscular disease; malignant hyperthermia.\n\nThe incidence of emergence agitation in the PACU was lower in the dexmedetomidine group compared to controls.\n\n    Huyan 2019\n\n360\nInclude: Age >= 65 yrs; ASA II-III; BMI 18-25 kg/m3; forced vital capacity > 80%; 1st second forced expiration > 70%;.Exclude: Hx of metabolic disorder (diabetes); discharge to ICU after surgery; preop delirium; new atrial fibrillation; cardiac arrest; stock blood infusion; hypoxemia (SpO2 < 90%, > 1 min).\n\nPostoperative delirium was seen 15.6% of patients receiving dexmedetomidine compared to 27.2% in the control group on postoperative day 1 and 0% on postoperative day 7 in both groups.\n\n    Larsen 2010\n\n495\nInclude: Age <65 with with a history of post op delirium; age>=65, elective TKR or THR.Exclude: Diagnosis of dementia; active alcohol use; history of alcohol abuse; allergy olanzapine; current use of antipsychotic.\n\nThe incidence of delirium was significantly lower in the olanzapine group than in the placebo group (14.3% vs 40.2%, Adjusted OR:0.2, CI: 0.1-0.4, p<0.001). However, delirium lasted longer in the olanzapine group (2.2 [SD\u00031.3] versus 1.6 [SD\u00030.7] days; p=0.02). The severity of delirium was also greater in the olanzapine-treated group than in the placebo group (16.44 [SD: 3.7] vs 14.5 [SD: 2.7]; p=0.02).\nHigh dropout rate, patients stratified by complexity of surgery\n    Wang 2022\n\n125\nInclude: Age 60-75 yrs; ASA I-II.Exclude: Cognitive dysfunction; adverse response to propofol, remifentanil, dexmedetomidine; cardiovascular disease; endocrine disease; liver or kidney dysfunction; alcohol, sedatives, or opioid use.\n\nThe mean MMSE score was similar between the dexmedetomidine and placebo groups on postoperative days 2 and 3 (25.2 vs 25.1, p=0.66; 25.4 vs 25.3, p=0.76).\n\n    Chitnis 2022\n\n70\nInclude: Age > 75; undergoing CABG or aortic valve replacement (AVR) surgery on cardiopulmonary bypass.Exclude: Dx of moderate dementia MMSE score < 20; hx of hypersensitivity to any medication in the study protocol.\n\nThere was no significant difference in QoR-40 scores (95% CI, -7.6 to 11.0; P= 1.0), the incidence of delirium (group Propofol, 42.4% vs group Dexmedetomidine, 24.2%, P=0.19) or mean duration of delirium (95% CI, -5.5 to 1.5; P=0.30).\n\n    Fukata 2017\n\n201\nInclude: Patients age >=75 years; elective abdominal surgery under general anesthesia or elective orthopedic surgery under general/spinal anesthesia.Exclude: Emergency surgery; preop NEECHAM <20; use of new antipsychotics, antidepressants, hypnotics, or anti-Parkinson agents 2 wks before surgery.\n\nAmong patients undergoing abdominal or orthopedic surgery, patients receiving 5 mg haloperidol (n=99) postoperatively, experienced less delirium on postoperative day 1 compared with patients receiving no treatment (n=100), 3% vs 13%, respectively, p=0.017. Adjusting for age, sex, preoperative cognition, and type of surgery, the risk (OR, 95% CI) of developing severe postoperative delirium in patients receiving haloperidol compared with no treatment was 0.31, 0.13-0.66.\n\n    Marcantonio 2001\n\n126\nInclude: Patients age >=65; surgical repair of hip fracture.Exclude: Metastatic cancer or other comorbid illness reducing life expectancy <6 months.\n\nIn patients undergoing emergency hip fracture repair, patients receiving daily proactive geriatrics consultation experienced less postoperative delirium compared with patients receiving usual care, 20/62 (32%) vs 32/64 (50%), RR=0.64 (95% CI: 0.37-0.98). When adjusting for prefacture dementia and ADL impairment, a difference in delirium was no longer detected, OR=0.6 (95% CI: 0.3-1.3).\nSubgroup analyses of patients with prefracture dementia did not detect a difference in postoperative dementia between the intervention and control groups, 13/20 (65%) vs 20/30 (67%), p=0.60. Subgroup analyses of patients with prefracture ADL impairment did not detect a difference in postoperative dementia between the intervention and control groups, 8/20 (40%) vs 13/31 (42%), p=0.60.\n    Li 2019\n\n164\nInclude: Patients age >=65; ASA physical status I-III; elective unilateral total hip replacement or total knee replacement.Exclude: Contraindications to spinal surgery (eg, aortic stenosis, coagulopathy, anticoagulant use, spinal cord disease, refusal of spinal anesthesia); severe hepatic or renal insufficiency; stroke or transient ischemic attack in 1 month; difficulty with neuropsychological assessment (<9 yr education or existing mental disorder).\n\nAmong patients undergoing THA or TKA with spinal anesthesia, patients receiving midazolam experienced more postoperative cognitive dysfunction at day 7 compared with patients receiving propofol,  28/54 (52%) v 10/55 (18%), p<0.001. A difference in cognitive dysfunction was not detected between patients receiving midazolam compared with dexmedetomidine, 28/54 (52%) vs 22/55 (40%), p=0.214. Differences were not detected in cognitive function among any of the groups at 1 year followup.\n\n    Hempenius 2013\n\n297\nInclude: Patients age >65; elective surgery for solid tumor; frail (defined as Groningen Frailty Indicator [screening instrument with 4 domains - physical, cognitive, social, psychological] score >3).Exclude: Non-frail; unable to complete questionnaires.\n\nIn frail patients undergoing elective surgery for solid tumors, a difference in delirium was not detected in patients receiving geriatric liaison interventions compared with patients receiving standard care, 12/127 (9.4%) vs 19/133 (14.3%), OR (95% CI): 0.63 (0.29-1.35). Differences in complications, and physical and mental scores, were also not detected between the groups.\n\n    Xiang 2022\n\n174\nInclude: Age 65-80 years; ASA II-III.Exclude: Dementia; unstable mental status or illness; hx of stroke; hx of gastric ulcer.\n\nCompared with placebo, methylprednisolone greatly reduced the incidence of delirium at 72 hours following surgery (9 [10.7%] vs 20 [23.8%], p = .03, OR = 2.22 [95% CI 1.05–4.59]).\n\n    Glumac 2021\n\n169\nInclude: Age 41-84 yrs.Exclude: Cerebrovascular incidence 3 years prior; mental illness; visual, hearing, or motor impairment; hx of cardiac or carotid surgery; adrenal gland disease; alcohol or drug abuse; MMSE < 26; Beck Depression score > 19; perioperative stroke.\n\nPostoperative cognitive decline 6 days after surgery (RR 0.510; 95% CI: 0.24 to 1.079, p=0.067) and 4 year after study conducted was lower in dexamethasone group compared to placebo (RR 0.456; 95% CI: 0.192 to 1.100, p=0.068).\n\n    Lu 2021\n\n808\nInclude: >=60; elective abdominal surgery; expected surgical duration of 1-6 hours.Exclude: Gastrointestinal motility disorders; previous abdominal surgery; severe hepatic or kidney dysfunction; second or third-degree heart blockage; bradyarrhythmia with a baseline rate lower than 50 beats/minute; mental disorders; history of difficult airway or delayed extubation; opioid medication misuse; allergy to dexmedetomidine or other anesthetics; preop gastrointestinal hemorrhage; emergency reoperations; ASA class IV or V.\n\nThe dexmedetomidine group had a significantly shorter time to first flatus. The incidence of delirium was comparable between the dexmedetomidine and control groups in the first 3 postoperative days.\n\n    Kalisvaart 2005\n\n430\nInclude: Patients age >=70 years; acute or elective hip surgery; at intermediate (1-2 risk factors) or high risk (3-4 risk factors) for postop delirium out of following: 1) visual impairment (worse than 20/70 after correction), 2) APACHE II >=16, 3) MMSE <=24, and 4) index of dehydration (blood urea nitrogen/creatinine ratio >=18).Exclude: Delirium at admission; no risk factors for postop delirium; haloperidol allergy history; cholinesterase inhibitor use; parkinsonism; epilepsy; levodopa treatment; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay >72 h after admission; prolonged QTc interval >460 ms (males) or >470 ms (females).\n\nDelirium incidence was 15.1% (32/212) among patients receiving haloperidol (1.5 mg daily from admission to 3 days postop) and 16.5% (36/218) among patients receiving placebo, (RR, 95% CI: 0.91, 0.59-1.44). Delirium severity (Delirium Rating Scale mean difference, 4.0 [95% CI: 2.0-5.8]) and delirium duration (mean difference in days, 6.4 [95% CI: 4.0-8.0]) were lower in the haloperidol group compared with the placebo group.\n\n    Fukata 2014\n\n121\nInclude: Patients age >=75 years; elective abdominal surgery under general anesthesia; elective orthopedic surgery under general/spinal anesthesia.Exclude: Emergency surgery; preop NEECHAM <20; periodic dosing with new or switched antipsychotics, antidepressants, hypnotics, or anti-Parkinson agents within 2 wks of surgery; previous treatment with haloperidol for delirium after surgery.\n\nAmong patients undergoing abdominal or orthopedic surgery, 25/59  (42%) patients receiving 2.5 mg haloperidol on days 1-3 postoperatively experienced delirium compared with 20/60 (33%) patients receiving no treatment, [adjusted OR (95% CI): 1.30 (0.54-3.17), p=0.558].\n\n    Chen 2020\n\n88\nInclude: Patients age >=60; ASA physical status I-II; MMSE >=25; normal kidney and liver function.Exclude: Hypertension, heart disease, diabetes history; cerebral hemorrhage, brain trauma, or cerrebral infarction history; mental illness or mental abnormality; alcohol or drug abusedeath during the study; significant abnormalities in study measures; serious adverse reactions during operation (difficult intubation, major bleeding, anaphylactic shock).\n\nIn patients undergoing radical resection for colorectal cancer, patients receiving dexmedetomidine (n=43) experienced higher MMSE scores compared with patients in the control group (n=45) on postoperative days 1 and 3, p<0.05 on both days. MMSE scores for the dexmedetomidine group were 27.3 +/- 0.8 and 28.8 +/- 0.9 on days 1 and 3 respectively, and the control group's scores were 21.1 +/- 0.5 and 22.5 +/- 0.8.\n\n    Ding 2021\n\n180\nInclude: Scheduled to undergo non-cardiac surgery.Exclude: Severe lung or heart diseases; renal or hepatic dysfunction;.\n\nFor older patients, intravenous anesthesia was a better anesthesia method because it has no distinct effect on the cognitive function of people after surgery.\n\n    Tan 2022\n\n99\nInclude: Age >60; undergoing upper GI endoscopy; ASA I-II.Exclude: Clinically significant cardiorespiratory instability; clinically significant renal or hepatic dysfunction; history of drug/alcohol abuse, neurological disease, auditory, or visual disturbances; pre-existing memory or cognitive impairment; and allergy to anesthetics.\n\nThe addition of 0.1 mg/kg of Remimazolam tosilate as an adjunct to opiate sedation not only achieves more stable perioperative hemodynamics, but also achieves acceptable neuropsychiatric function in elderly patients.\n\n    Wang 2012\n\n457\nInclude: Patients age >=65 years; noncardiac surgery admitted to ICU.Exclude: Schizophrenia; epilepsy; parkinsonism; cholinesterase inhibitor use; levodopa treatment; inability to communicate (coma, profound dementia, language barrier); haloperidol or other neuroleptic use during or after anesthesia; neurosurgery; unlikely survival >24 hrs; prolonged corrected QT >=460 for men or >=470 for women at baseline.\n\nAmong patients undergoing non-cardiac surgery, 35/229  (15%) patients receiving 5 mg haloperidol IV over 12 h postoperatively experienced delirium during the first 7 days post-surgery compared with 53/228 (23%) patients receiving no treatment (p=0.031). A difference was not detected in 28-day mortality between the haloperidol group (0.9%) and the control group (2.6%), p=0.175.\n\n    Javaherforoosh 2021\n\n60\nInclude: >=30 years; elective on-pump CABG; ASA class II-III; minimum ejection fraction of 30%;.Exclude: Presence of melatonin contraindications; allergy to the drug; chronic or recent use of melatonin or hypnotic drugs; receiving barbiturates or or antipsychotics; a history of kidney or liver disease or chronic pulmonary disease; history of neurological or psychological diseases; alcohol consumption; inability to communicate verbally; occurrence of serious and like threatening events during or after.\n\nMelatonin may be effective in reducing the severity of delirium after cardiac surgery. The effect of melatonin asa delirium prevention agent should be considered in patients admitted in the cardiovascular intensive care.\n\n    Heilmann 2016\n\n253\nInclude: Age >= 18 yrs; ability to communicate.Exclude: Severe mental and/or physical burden.\n\nA reduction in anxiety was seen in patients with expanded preoperative evaluation compared to standard care when measured by STOA-S (...).\n\n    Aizawa 2002\n\n42\nInclude: Age 70-86 yrs.Exclude: Liver cirrhosis; liver dysfunction; respiratory disturbance; metal disorder; visual impairment; emergency surgery.\n\nThe incidence of postoperative delirium, measured using DSM-IV criteria, was (35.0%) in the non delirium prevention protocol group and (5.0%) in the delirium prevention protocol group (p = 0.023).\n\n    Shi 2021\n\n297\nInclude: Age > 60 yrs; ICU admission.Exclude: Mental illness and epilepsy; neurologic disease; brain injury or neurosurgery; high cholesterol with diabetes.\n\nThe incidence of postoperative delirium was significantly lower in the melatonin group than in the placebo group (27.0% vs. 39.6%, respectively, p = 0.02). No difference was detected in 30-day all-cause mortality (12.2% vs. 14.1%, p = 0.62).\n\n    \n      Nonrandomized Trial\n    \n    Kratz 2015\n\n114\nInclude: Patients age >70; no clinically manifest signs of delirium.Exclude: Advanced dementia; severe delirium preoperatively; end-stage disease.\n\nPatients in a general surgical ward receiving care from a nurse trained in delirium prevention experienced less postoperative delirium compared with patients in a general surgical ward receiving usual care, 5% (95% CI: 0-11%) vs 21% (95% CI: 11-32%).\nThis study was part of the Hospital Elder Life Program (HELP).\n    \n      Before-After/Time Series\n    \n    Yamasaki 2019\n\n21\nInclude: Patients age >=65 years; hepatectomy.Exclude: Laparoscopic hepatectomy; ICU admission following hepatectomy.\n\nIn patients undergoing hepatectomy, patients receiving omeprazole experienced less postoperative delirium compared with patients receiving famotidine, 3/11 ((27%) vs 9/10 (90%), p<0.01.\n\n    Lester 2022\n\n492\nInclude: Patients age >=75; elective general, gynecologic-oncology, or orthopedic surgery.Exclude: None described.\n\nIn patients undergoing general, gynecologic-oncology, or orthopedic surgeries, differences were not detected in postoperative delirium, discharge location, 30-day readmission, or 30-day mortality in patients receiving expanded comprehensive interdisciplinary preoperative assessments compared with patients receiving usual care.\nResults are from 1 center of 11 sites involved in the American College of Surgeons' Geriatric Surgery Quality Program during the Alpha pilot.\n    Adogwa 2017\n\n125\nInclude: Patients age >=65; elective lumbar decompression and fusion surgery; back pain and/or radiculopathy; radiographic evidence of thoracolumbar deformity; prior failed nonsurgical treatment; underwent multilevel lumbar decompression and fusion.Exclude: Severe coexisting pathology that would confound outcomes; nonambulatory.\n\nIn patients undergoing lumbar decompression and fusion surgery, differences were not detected in complications or postoperative delirium in patients receiving additional care from a geriatrician compared with patients receiving standard care. More patients in the intervention group were discharged to home compared with the standard care group, 54% vs 24%, p=0.01.\n\n    Lau 2013\n\n1753\nInclude: Patients age >65; hip fracture.Exclude: Pathological fractures, multiple fractures, and hip fractures transferred from other specialty.\n\nIn patients undergoing hip fracture surgery, differences were not detected in inpatient mortality, 30-day mortality, or complication rates following the implementation of a geriatric hip fracture clinical pathway. Length of stay decreased following the clinical pathway, p<0.05.\n\n    Richter 2005\n\n62\nInclude: Patients age >60; undergoing pelvic floor surgery.Exclude: None described.\n\nIn women undergoing pelvic floor surgery, differences in SF-36 physical and mental scores were not detected at 6-week followup in patients receiving enhanced preoperative assessment compared with patients receiving usual care (6-week physical: 39.0 +/- 8.3 vs 37.6 +/- 7.5; 6-week mental: 55.5 +/- 9.5 vs 53.7 +/- 8.6). Differences in SF-36 scores were not detected in 6-month followup between the groups (6-month physical: 45.3 +/- 10.9 vs 49.2 +/- 10.4; 6-month mental: 56.3 +/- 7.3 vs 53.9 +/- 10.8).\n\n    Hall 2017\n\n9153\nInclude: Patients presenting for major elective surgical procedures.Exclude: Cardiac surgery.\n\nIn a large Veterans Affairs hospital, overall 30-day mortality decreased from 1.6% (84/5275) to 0.7% (26/3878) after the Frailty Screening Initiative was implemented, adjusted OR (95% CI): 3.5 (1.8-7.0). Six month and 1 year mortality rates also decreased following the screening initiative, OR (95% CI): 2.9 (2.0-4.2) and 3.0 (2.1-4.2), respectively. The multivariate models controlled for age, frailty, and predicted mortality.\nImprovement in mortality rates was greatest among frail patients (12.2% [24/197] to 3.8% [16/424]), though mortality rates also decreased among robust patients (1.2% [60/5078] to 0.3% [10/3454]).\n\nAll intervention patients were assessed for frailty with Risk Analysis Index, and 6.8% were identified as frail. Those who were deemed frail received additional review by chief of surgery in regards to surgical decision making.\n    Romano 2021\n\n181\nInclude: Patients undergoing elective hip or knee arthroplasty replacement.Exclude: None described.\n\nIn patients undergoing total hip or knee arthroplasty, patients receiving care under a fast-track recovery system experienced higher rates of home discharge compared with patients prior to the fast-track system, adjsuted OR (95% CI): 41.9 (12.1-144.9) and shorter length of stay, p<0.01.\nComplications also reported, but all of the following combined: pain, range of motion, infections, surgical wound, hypotonus, tendonitis, hematoma, joint effusion, periprosthetic joint infection, and thromboembolioc events. No differences in complications detected at 1 month; intervention group experiencing lower rate of complications at 6-, 12-, 24-, and 36-months followup compared with control group.\n    Coventry 2017\n\n446\nInclude: Patients age >=65; hip fracture.Exclude: None described.\n\nIn patients with hip fracture, patients receiving care managed by a geriatrician or comanaged by an orthopedic surgeon and a geriatrician were more likely to be diagnosed with postoperative delirium compared wtih patients receiving care managed by an orthopedic team alone, adjusted OR (95% CI): 2.5 (1.5-4.3) and 3.2 (1.9-5.3), respectively. Difference in 30-day mortality between the 3 groups was not detected.\nPreoperative assessments completed for: 22.4% managed by orthopedic team; 98.5% managed by geriatrics team; and 75.4% co-managed by orthopedic and geriatric teams.\n    Indrakusuma 2015\n\n443\nInclude: Patients age >=70; colorectal carcinoma undergoing elective resection.Exclude: Acute operation; transanal endoscopic microsurgery.\n\nIn patients undergoing colorectal carcinoma resection, differences were not detected in 30-day mortality or postoperative delirium in patients screened with the Identification of Seniors at Risk questionnaire compared with patients receiving standard preoperative care (mortality: 14/221 [6%] vs 17/222 [8%], p=0.71; delirium: 22/221 [10%] vs 27/222 [12%], p=0.55).\nOf the 221 patients screened preoperatively, 50 (23%) were referred for a Geriatric Daycare Examination by an in-house geriatrician. The assessment included a full medical history, full physical exam, lab tests, MMSE, Geriatric Depression Scale, and Mini Nutritional Assessment. Geriatricians may then advise interventions (eg, haloperidol prophylaxis, blood transfusions, supplements). A case-control analysis compared the 50 patients referred for the additional assessment with patients who did not need the additional assessment. Differences in mortality and delirium were not detected.\n    Zhang 2017\n\n278\nInclude: Patients age >=18; ICU stay >24 h; undergoing coronary artery bypass graft.Exclude: Mental disease or delirium at admission; did not awaken within first 24 h post-surgery.\n\nIn patients undergoing coronary artery bypass graft, patients managed under a nursing protocol targeting risk factors for delirium experienced less postoperative delirium compared with patients managed under usual care, 19/141 (13%) vs 41/137 (30%), p=0.001.\n\n    Bakker 2014\n\n241\nInclude: Patients age >=70; expected length of stay >48 h.Exclude: Contagious disease; terminally ill; treatment by medical specialist from department outside of study.\n\nDifferences were not detected in delirium, neurocognitive delay, or 30-day readmission in patients receiving care after CareWell in Hospital program implementation compared with patients receiving care before implementation of the program.\n\n    Bjorkelund 2010\n\n276\nInclude: Patients age >=65 years; hip fracture; cognitively intact based on Short Portable Mental Status Questionnaire (>=8 correct answers).Exclude: History of cognitive impairment; multi-trauma.\n\nIn patients undergoing hip fracture surgery, patients receiving care within a multi-factorial intervention program experienced lower postoperative delirium rates compared with patients receiving care prior to the program implementation, 29/131 (22%) vs 45/132 (34%), p=0.031. Difference in 30-day mortality was not detected between the groups.\n\n    Vochteloo 2011\n\n1056\nInclude: Patients age >=65; hip fracture due to low energy trauma, non-pathologic origin.Exclude: None mentioned.\n\nIn patients undergoing hip fracture surgery, a difference in delirium incidence was not detected in patients assessed by the Risk Model for Delirium compared with patients receiving usual care.\nDelirium incidence in intervention group was 27% compared with 3 pre-intervention years of 29%, 24%, and 28%.\n    Braude 2017\n\n242\nInclude: Patients age >=65; elective or emergency urological surgery.Exclude: None described.\n\nIn patients undergoing urologic surgery, patients receiving geriatric liaison services experienced fewer medical and surgical complications compared with patients receiving usual care, medical OR (95% CI): 0.26 (0.10-0.54) and surgical OR (95% CI): 0.16 (0.05-0.49). Differences were not detected in unplanned readmissions between the groups.\nStudy included patients undergoing non-surgical procedures (15 in each arm) and emergency admissions (32 in control group and 41 in intervention group).\n    Ernst 2014\n\n310\nInclude: Patients undergoing elective surgery; surgical palliative care consultations.Exclude: None described.\n\nIn a large Veterans Affairs hospital, overall 30-day mortality in patients receiving palliative care consultations decreased from 32% (51/160) to 21% (32/150) after the Frailty Screening Initiative was implemented, p<0.05. Six month and 1 year mortality rates also decreased following the screening initiative, both p<0.05. After initiation of the screening program, palliative care consultations were more often ordered prior to surgery (52% vs 26.%, p<0.05) and mortality rates were reduced when palliative care was ordered prior to surgery (adjusted OR [95% CI]: 0.5 [0.3-0.9], p=0.02).\nAll intervention patients were assessed for frailty with Risk Analysis Index, and approximately 10% were identified as frail. Those who were deemed frail received additional review by chief of surgery and were strongly encouraged to undergo preoperative palliative care consultation.\n    Palmbergen 2012\n\n642\nInclude: Patients age >18; elective coronary artery bypass graft or coronary artery bypass graft plus procedure (including revascularization of coronary arteries with valve reconstruction, Maze procedure or aorta ascendens replacement).Exclude: Redo-coronary artery bypass graft; off-pump coronary artery bypass graft.\n\nIn patients undergoing coronary artery bypass graft, patients who were exposed to a screening protocol for delirium (Haga Brain Care Strategy) experienced lower rates of postoperative delirium compared with patients who were not screened, 30/409 (7%) vs 31/233 (13%), adjusted OR (95% CI): 0.37 (0.16-0.86).\nThe screening protocol involved transcranial Doppler (TCD) screening and perioperative cerebral oximetry monitoring. Due to logistical reasons, not all patients in the intervention group received the screening and monitoring. TCD and monitoring occurred in 1.7% of the control group and 34.0% of the intervention group.\n    Miyata 2017\n\n82\nInclude: Age > 70 yrs; undergoing lung resection.Exclude:  Not specified.\n\nThere were no incidence of postoperative delirium in patients taking ramelteon compared to 9% of controls.\n\n    Souwer 2018\n\n149\nInclude: Patients age >=75; surgical resection for colorectal cancer.Exclude: None described.\n\nIn patients undergoing resection for colorectal cancer, patients receiving a multidisciplinary preoperative assessment experienced fewer cardiac complications (p=0.01) and shorter length of stay (p=0.047) compared with patients receiving usual care. Differences were not detected between the groups in 30-day mortality, 1-year mortality, readmission, or surgical complications.\n\n    Hokuto 2020\n\n309\nInclude: Patients who underwent liver resection at Nara Medical University (Nara, Japan) from January 2014 to August 2018 were retrieved (from registration).Exclude: Patients who underwent biliary reconstruction; patients who could not take water or medicine on POD 1 were excluded (from registration).\n\nThe incidence of postoperative delirium was significantly lower in the ramelteon group compared to controls (5.8% vs. 15.1%, p = 0.035).\n\n    Ushida 2009\n\n122\nInclude: Patients age >50 years; cervical decompression surgery.Exclude: Pre-existence of dementia or other psychological disorder.\n\nPatients undergoing cervical decompression surgery following a change in protocol (reduction in methylprednisolone dose and encouragement of free body movement) experienced lower incidence of postoperative delirium compared with patients prior to protocol changes [3/41 (7%) vs 23/81 (28%), p=0.009].\n\n    \n      Prospective Cohort\n    \n    Wang 2021\n\n1266\nInclude: Age 65-85 years, English fluency.Exclude: Brain or cardiac surgery, no written consent.\n\nPremedication using midazolam was not associated with higher incidence of delirium (23%) on the first postoperative day in older patients undergoing major noncardiac surgery compared to no midozolam (25%; OR = 0.91; 95% CI, 0.65-1.29; p=0.67).\n\n    Konishi 2018\n\n300\nInclude: Age 60 or older, elective first-time total hip replacement for osteoarthritis; living within reasonable proximity to the hospital to allow investigators to travel to participant's homes for cognitive testing.Exclude: Pre-existing neurological or clinically evident neurovascular disease; MMSE score less than 26; Clinical Dementia Rating Scale more than 1; anticipated difficulty with neuropsychological assessment; poor English; ability to perform neuropsychological testing; blindness; deafness; critical medical problems such as ASA physical status IV or higher;.\n\nThere was no statistically significant difference between the incidence of POCD at an timepoint with sevoflurane compared to propofol.\n\n    Bickel 2008\n\n200\nInclude: Age > 60 yrs.Exclude: Dementia; diagnosis of terminal illness.\n\nDelirium occurred in 24.4% of patients who used psychotropic drugs preoperatively.\nDelirium risk factor from a prospective cohort study of patients undergoing hip surgery. The fully adjusted OR for cognitive impairment among patients with delirium in comparison with the controls without delirium amounted to 4.6 (0.9–42.2) after 8 months and rose to 41.2 (4.3–396.2) after 38 months. Among the 41 patients with delirium a significantly higher proportion (36.6%) died than among the 158 without delirium (10.8%), but after adjustment for confounding variables there remained only a nonsignificant tendency toward an increased mortality risk (1.3 at 8 months vs 1.7 at 38 months).\n    Duprey 2022\n\n566\nInclude: Age 70 years or older English speaking (English need not be first language) Scheduled for eligible high-risk surgery: Orthopedic (total hip or knee replacement; lumbar, cervical, or sacral laminectomy)\nVascular (lower extremity arterial bypass surgery; open abdominal aortic aneurysm repair;\nlower extremity amputation)\nGeneral (open or laparoscopic colectomy)\nPlanned general or regional anesthesia Scheduled at least 6 days before surgery to allow adequate time for the baseline assessment Planned admission to the hospital for at least 2 days Living within 40 miles from study hospitals Exclusion criteria\nActive delirium.Exclude: Active delirium Dementia (dementia diagnosis or score <69 or education-adjusted equivalent on baseline 3MS\ncognitive test)\nHospitalization within 3 months before enrollment to minimize risk of recent delirium Terminal condition with life expectancy < 6 months (eg, metastatic cancer, pancreatic cancer,\nor receiving palliative care)\nInability to perform cognitive tests because of legal blindness or severe deafness.\n\n134 (24%) developed delirium during hospitalization. \n\nPreoperative medication associations with delirium: \nbenzodiazepines (RR, 1.44; 95% CI, 0.85–2.44)\nbeta-blocker (RR, 1.38; 95% CI, 0.94–2.05)\nNSAID (RR, 1.12; 95% CI, 0.77–1.62)\nopioid (RR, 1.22; 95% CI, 0.82–1.82) \nstatin (RR, 1.34; 95% CI, 0.92–1.95)\n\nPostoperative medication associations with delirium (before delirium): \nbenzodiazepine (aHR, 3.23; 95% CI, 2.10–4.99)\nantipsychotic (aHR, 1.48; 95% CI, 0.74–2.94) \nopioid (aHR, 0.82; 95% CI, 0.62–1.11) \n\nAntipsychotic use (either presurgery or postsurgery) was associated with a 0.34 point (standard error, 0.16) decrease in general cognitive performance at 1 month through its effect on delirium (P = .03), despite no total effect being observed.\n\n    Barreto Chang 2022\n\n98\nInclude: Age >= 65 yrs.Exclude: Inability to read, understand, or speak English.\n\nIncidence of postoperative delirium occurred in 32% of patients in the ketamine group and 18% of patients in the control group.\n\n    \n      Retrospective Cohort\n    \n    Park 2020\n\n1254\nInclude: Adult patients who underwent non-cardiac surgery under general anesthesia with troponin measurement before surgery and repeated measurement within 7 postoperative days.Exclude:  Not specified.\n\n30 day mortality was higher in the TIVA group than the volatile group (17% vs 9.1%).\n\n    Oh 2019\n\n3084\nInclude: Patients ages >19; underwent curative lung resection surgery for primary nonsmall cell lunch cancer (NSCLC).Exclude: Patients with end stage rental disease; defined as requiring renal replacement therapy or having pre-operative estimated glomerular filtration rate less than 15 ml min -1 1.73 m-2; those with incomplete or missing medical records; those who required repeat lung cancer after surgery during the study period.\n\nNo significant difference was found in the incidence of postoperative AKI after lung resection surgery between patients who received TIVA and sevoflurane.\n\n    Shimizu 2010\n\n265\nInclude: All adult patients undergoing gastrointestinal surgery.Exclude: Patients aged <20; ASA physical status IV-VI; laparoscopic surgeries.\n\nAfter matching, standardized infection ratio after sevoflurane anesthesia was 1.89, which was significantly lower than after propofol anesthesia.\n\n    Koo 2016\n\n1934\nInclude: Adult inpatients who underwent elective colorectal surgery under general anesthesia; ICD-9-CM procedure codes: 45.7, 45.8, 46.1, 46.52, 48.5, 48.63, and 17.3.Exclude:  Not specified.\n\nStudy results suggest that intravenous anesthesia may have beneficial effects for reducing surgical site infection in colorectal surgery compared to volatile anesthesia (2 [0.5%] vs 10 [2.6%], OR = 5.0 [95% CI = 1.1-22.8], respectively).\nNotes it was registered at ClinicaTrials but no record number provided.\n    Diener 2015\n\n105\nInclude: Older than 68 years old; provided informed consent ;scheduled for major noncardiac surgery under general anesthesia, including general, spine, urologic, or thoracic surgery.Exclude: Intracranial surgery; cardiac surgery; pre-existing neuropsychiatric disease; history of cerebrovascular accident with residual deficits; baseline MMSE score < 20; unable to consent for study participation; unable to speak English.\n\nThe median Bispectral Index value for patients who developed POCD was similar to patients who did not. Patients who develop POCD spent less time with Bispectral Index < 45 minutes and burst suppression. Patients who developed POCD spent less time in EEG burst suppression and less time in deep states.\n\n    Jakobsen 2007\n\n12678\nInclude: All procedures performed since January 1999.Exclude: Reoperations during the same hospitalization; heart transplants where cardioprotection was not relevant; procedures primarily involving surgery on the ascending or descending aorta.\n\nThe 30-day mortality was lower after sevoflurane (2.84%) versus propofol (3.30%) although not significantly. No difference was found in the incidence of postoperative myocardial infarction.\n\n    Jeong 2016\n\n527\nInclude: Age >=65 yrs.Exclude: Refused surgery, did not have cancer.\n\n8.5 % of patients given delirium-inducing medication were diagnosed with postoperative delirium compared to 0.7% of patients without the medication.\n\n    Shin 2021\n\n715\nInclude: Age >20 years; undergone heart valve or coronary artery bypass graft surgery with cardiopulmonary bypass.Exclude: Patients who had been preoperatively diagnosed with neuropsychological diseases such as dementia or Parkinson; visual disturbances, hearing loss, or reoperation due to postoperative complications; required postoperative sedation for any reason.\n\nThe overall incidence of postoperative delirium after cardiac surgery did not differ between patients receiving sevoflurane and dexmedetomidine based vs propofol based anesthesia.\n\n    Goins 2018\n\n116\nInclude: Patients undergoing transcatheter aortic valve replacement; general anesthesia.Exclude:  Not specified.\n\nThe odds of delirium were lower in patients with TIVA compared to volatile anesthesia after adjusting. No significant difference in hospital or intensive care unit length of stay was seen after adjusting for procedural characteristics.\n\n    Mangusan 2015\n\n656\nInclude: Not specified.Exclude:  Not specified.\n\nPostoperative delirium occurred in 31% patients who took oral benzodiazepines after cardiac surgery and in 19.8% of patients taking Ketorolac.\n\n    Kishimoto 2018\n\n21899\nInclude: Patients who underwent TKA with general anesthesia.Exclude: A history of prior THA within 30 days of surgery; a history of prior contralateral TKA within 30 days of surgery; age <40 years; surgical site infection treatment during the hospitalization with antibiotics other than anti-methicillin- resistant Staphylococcus aureus (MRSA) drugs and aminoglycosides; missing data on hospital characteristics; missing data on duration of anesthesia; missing data on type of intraoperative analgesia; use of ketamine for anesthesia induction; and diagnosis of gout or pseudogout.\n\nPropensity score analysis suggested no significant association between the choice of anesthetic maintenance agent and the occurrence of suspected early-onset periprosthetic joint infection in patients undergoing total knee arthroplasty (1.3% propofol vs 1.7% sevoflurane [relative risk = 0.76; 95% CI = 0.55 to 1.04; P = 0.10]). The mean (SD) length of stay in the propofol group was significantly longer than in the sevoflurane group (32.5 (18.4) days vs 31.4 (14.4) days, respectively [mean difference = 1.1; 95% CI = 0.5 to 1.8; P < 0.001]).\n\n    Bellas 2020\n\n491\nInclude: Patients age >=50; surgery for isolated fragility hip fracture (defined as a fall from a height of standing or less).Exclude: Additional skeletal trauma; periprosthetic fracture.\n\nIn patients undergoing hip fracture surgery, patients receiving preoperative specialty consults experienced extended lengths of stay (adjusted OR [95% CI]: 2.7 [1.8-4.0]) and higher 30-day readmission rates (adjusted OR [95% CI]: 2.1 [1.1-4.1]) compared with patients who did not receive preoperative specialty consults. Differences in 30-day mortality were not detected between the groups.\nOdds ratios adjusted for age and Charlson comorbidity index.\n    Wu 2018\n\n1363\nInclude: ASA score of I,II, or III; underwent elective colon cancer open surgery for tumor-node-metastasis stage I to IV colon cancer;.Exclude: Combined propofol anesthesia with inhalation or epidural anesthesia; incomplete data; age less than 20 years;.\n\nIn a matched analysis, the propofol-treated group had better survival, irrespective of lower tumor-node-metastasis stage or higher tumor-node-metastasis stage and irrespective presence of metastases or absence of metastases.\n\n    Cho 2021\n\n3045\nInclude: End-stage renal disease (ESRD) patients on hemodialysis in the institutional database; age 20-80; underwent general anesthesia.Exclude: Patients who had undergone cardiac surgery, cancer surgery, organ transplantation, or emergency surgery; patients who received both forms of anesthesia within the study period, either during the same surgical procedure or for additional procedures.\n\nAfter the multivariate analysis, factors associated with a significantly lower MACE risk included preoperative chloride concentration, baseline SBP, and propofol TIVA.\n\n    Slor 2011\n\n526\nInclude: Patients age >=70; acute or elective hip surgery.Exclude: Delirium at admission; inability to participate in interviews (profound dementia, language barrier, intubation, respiratory isolation, aphasia, coma, terminal illness); surgery delay >72 h after admission; cholinesterase inhibitor use; parkinsonism; levodopa treatment; epilepsy; prolonged QTc interval >460 ms (males) or >470 ms (females) on ECG.\n\nIn this secondary analysis of RCT data, 18/189 (9.5%) patients receiving general anesthesia and 42/337 (12.5%) patients receiving regional anesthesia developed postoperative delirium (OR, 95% CI: 0.81, 0.43-1.52).\nRisk factors for delirium (age, baseline cognitive impairment, haloperidol prophylaxis) did not differ between the general and regional groups.\n    van der Vlies 2020\n\n466\nInclude: Patients age >=70; confirmed colorectal adenocarcinoma suitable for elective curative surgery.Exclude: Neuroendocrine tumors; transanal endoscopic microsurgery.\n\nA retrospective cohort showed that patients who were frail and referred to a multidisciplinary team for care experienced similar complication rates, 30-day mortality, and readmission rates as non-frail patients receiving standard care. However, frailty was associated with overall mortality, OR (95% CI): 2.6 (1.1-6.1).\n19/146 (13%) in MDT group and 14/320 (4%) in non-MDT group decided against surgery. The multidisciplinary team group was older; more female; and had higher ASA status, cardiovascular comorbidities, diabetes, alcohol use, weight loss, impaired mobility, impaired cognition, polypharmacy, anemia, and renal impairment.\n    \n      Case-Control\n    \n    Nandi 2014\n\n463\nInclude: Patients undergoing primary or revision total hip or knee arthroplasty under general anesthesia.Exclude: Spinal anesthesia; antipsychotic drug use.\n\nA case-control study of patients undergoing THA or TKA, reported an increased risk of postoperative delirium among patients administered benzodiazepines during hospital stay compared with patients not receiving benzodiazepines [adjusted OR (95% CI): 9.68 (4.30-21.79)].\nOR adjusted for sex, preop alcohol use, and preop depression.\n    Choi 2019\n\n58\nInclude: Patients with postoperative acute lung injury after lung resection surgery for lung cancer.Exclude: Respiratory distress due to respiratory/systemic infection.\n\nIn a case-control study of patients developing acute lung injury after lung resection surgery, patients administered corticosteroids early (within 72 h) experienced less postoperative delirium compared with patients receiving corticosteroids later  (after 72 h), 10/42 (24%) vs 10/16 (63%), p=0.012. Differences were not detected between the groups in complications or length of stay.\nPatients receiving early treatment with corticosteroids had greater improvements in lung injury score (primary outcome) compared with patients receiving later treatment; however, no difference was detected in mechanical ventilation weaning within 7 days (primary outcome).\n  \n  \n  \n\n\n\n\n\n\n\n\n\n\n\nReferences\n\n1. Adogwa O, Elsamadicy AA, Vuong VD, et al. Geriatric comanagement reduces perioperative complications and shortens duration of hospital stay after lumbar spine surgery: A prospective single-institution experience. J Neurosurg Spine. 2017;27(6):670-675. doi:10.3171/2017.5.Spine17199\n\n\n2. Aizawa K, Kanai T, Saikawa Y, et al. A novel approach to the prevention of postoperative delirium in the elderly after gastrointestinal surgery. Surg Today. 2022;32(4):310-314. doi:10.1007/s005950200044\n\n\n3. Avidan MS, Maybrier HR, Abdallah AB, et al. Intraoperative ketamine for prevention of postoperative delirium or pain after major surgery in older adults: An international, multicentre, double-blind, randomised clinical trial. Lancet. 2017;390(10091):267-275. doi:10.1016/s0140-6736(17)31467-8\n\n\n4. Azeem TMA, Yosif NE, Alansary AM, Esmat IM, Mohamed AK. Dexmedetomidine vs morphine and midazolam in the prevention and treatment of delirium after adult cardiac surgery; a randomized, double-blinded clinical trial. Saudi Journal of Anaesthesia. 2018;12(2):190-197. doi:10.4103/sja.SJA{\\_}303{\\_}17\n\n\n5. Bakker FC, Persoon A, Bredie SJH, et al. The CareWell in hospital program to improve the quality of care for frail elderly inpatients: Results of a before-after study with focus on surgical patients. Am J Surg. 2014;208(5):735-746. doi:10.1016/j.amjsurg.2014.04.009 10.1016/j.amjsurg.2014.04.009. Epub 2014 Jun 27.\n\n\n6. Barreto Chang OL, Kreuzer M, Morgen DF, Possin KL, Garcia PS. Ketamine associated intraoperative electroencephalographic signatures of elderly patients with and without preoperative cognitive impairment. Anesth Analg. Published online June 22, 2022. doi:10.1213/ANE.0000000000005875\n\n\n7. Bellas N, Stohler S, Staff I, et al. Impact of preoperative specialty consults on hospitalist comanagement of hip fracture patients. J Hosp Med. 2020;15(1):16-21. doi:10.12788/jhm.3264\n\n\n8. Bickel H, Gradinger R, Kochs E, Förstl H. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. Dement Geriatr Cogn Disord. 2008;26(1):26-31. doi:10.1159/000140804\n\n\n9. Bjorkelund KB, Hommel A, Thorngren KG, Gustafson L, Larsson S, Lundberg D. Reducing delirium in elderly patients with hip fracture: A multi-factorial intervention study. Acta Anaesthesiol Scand. 2010;54(6):678-688. doi:10.1111/j.1399-6576.2010.02232.x 10.1111/j.1399-6576.2010.02232.x. Epub 2010 Mar 15.\n\n\n10. Bornemann-Cimenti H, Wejbora M, Michaeli K, Edler A, Sandner-Kiesling A. The effects of minimal-dose versus low-dose s-ketamine on opioid consumption, hyperalgesia, and postoperative delirium: A triple-blinded, randomized, active- and placebo-controlled clinical trial. Minerva Anestesiol. 2016;82(10):1069-1076. https://www.ncbi.nlm.nih.gov/pubmed/27327855\n\n\n11. Braude P, Goodman A, Elias T, et al. Evaluation and establishment of a ward-based geriatric liaison service for older urological surgical patients: Proactive care of older people undergoing surgery (POPS)-urology. BJU Int. 2017;120(1):123-129. doi:10.1111/bju.13526\n\n\n12. Cai Y, Hu H, Liu P, et al. Association between the apolipoprotein E4 and postoperative cognitive dysfunction in elderly patients undergoing intravenous anesthesia and inhalation anesthesia. Anesthesiology. 2012;116(1):84-93. doi:10.1097/ALN.0b013e31823da7a2\n\n\n13. Chawdhary AA, Kulkarni A, Nozari A. Substitution of propofol for dexmedetomidine in the anaesthetic regimen does not ameliorate the post-operative cognitive decline in elderly patients. Indian J Anaesth. 2020;64(10):880-886. doi:10.4103/ija.IJA{\\_}365{\\_}20\n\n\n14. Chen H, Li F. Effect of dexmedetomidine with different anesthetic dosage on neurocognitive function in elderly patients after operation based on neural network model. World Neurosurg. 2020;138:688-695. doi:10.1016/j.wneu.2020.01.012\n\n\n15. Chen J, Yan J, Han X. Dexmedetomidine may benefit cognitive function after laparoscopic cholecystectomy in elderly patients. Exp Ther Med. 2013;5(2):489-494. doi:10.3892/etm.2012.811\n\n\n16. Chitnis S, Mullane D, Brohan J, et al. Dexmedetomidine use in intensive care unit sedation and postoperative recovery in elderly patients post-cardiac surgery (DIRECT). J Cardiothorac Vasc Anesth. 2022;36(3):880-892. doi:10.1053/j.jvca.2021.09.024\n\n\n17. Cho HB, Kim MG, Park SY, et al. The influence of propofol-based total intravenous anesthesia on postoperative outcomes in end-stage renal disease patients: A retrospective observation study. PLoS One. 2022;16(7):e0254014. doi:10.1371/journal.pone.0254014\n\n\n18. Choi H, Shin B, Yoo H, et al. Early corticosteroid treatment for postoperative acute lung injury after lung cancer surgery. Ther Adv Respir Dis. 2022;13:1753466619840256. doi:10.1177/1753466619840256\n\n\n19. Coventry LS, Nguyen A, Karahalios A, Roshan-Zamir S, Tran P. Comparison of 3 different perioperative care models for patients with hip fractures within 1 health service. Geriatric Orthopaedic Surgery and Rehabilitation. 2017;8(2):87-93. doi:10.1177/2151458517692651\n\n\n20. Dai Z, Lin M, Li Y, et al. Sevoflurane-remifentanil versus propofol-remifentanil anesthesia during noncardiac surgery for patients with coronary artery disease - a prospective study between 2016 and 2017 at a single center. Med Sci Monit. 2022;27:e929835. doi:10.12659/MSM.929835\n\n\n21. Deiner S, Luo X, Lin HM, et al. Intraoperative infusion of dexmedetomidine for prevention of postoperative delirium and cognitive dysfunction in elderly patients undergoing major elective noncardiac surgery: A randomized clinical trial. JAMA Surg. 2017;152(8):e171505. doi:10.1001/jamasurg.2017.1505\n\n\n22. Deiner S, Luo X, Silverstein JH, Sano M. Can intraoperative processed EEG predict postoperative cognitive dysfunction in the elderly? Clin Ther. 2015;37(12):2700-2705. doi:10.1016/j.clinthera.2015.11.004\n\n\n23. Dieleman JM, Nierich AP, Rosseel PM, et al. Intraoperative high-dose dexamethasone for cardiac surgery: A randomized controlled trial. JAMA. 2012;308(17):1761-1767. doi:10.1001/jama.2012.14144\n\n\n24. Ding DF, Wang P, Jiang YX, Zhang XP, Shi W, Luo YW. Effects of apolipoprotein epsilon epsilon4 allele on early postoperative cognitive dysfunction after anesthesia. Anaesthesist. 2022;70(Suppl 1):60-67. doi:10.1007/s00101-021-00972-1\n\n\n25. Ding L, Zhang H, Mi W, et al. Effects of dexmedetomidine on anesthesia recovery period and postoperative cognitive function of patients after robot-assisted laparoscopic radical cystectomy. Int J Clin Exp Med. 2015;8(7):11388-11395.\n\n\n26. Djaiani G, Silverton N, Fedorko L, et al. Dexmedetomidine versus propofol sedation reduces delirium after cardiac surgery: A randomized controlled trial. Anesthesiology. 2016;124(2):362-368. doi:10.1097/aln.0000000000000951\n\n\n27. Du X, Song F, Zhang X, Ma S. Protective efficacy of combined use of parecoxib and dexmedetomidine on postoperative hyperalgesia and early cognitive dysfunction after laparoscopic cholecystectomy for elderly patients. Acta Cir Bras. 2019;34(9):e201900905. doi:10.1590/s0102-865020190090000005\n\n\n28. Duprey MS, Devlin JW, Griffith JL, et al. Association between perioperative medication use and postoperative delirium and cognition in older adults undergoing elective noncardiac surgery. Anesth Analg. 2022;134(6):1154-1163. doi:10.1213/ANE.0000000000005959\n\n\n29. Egawa J, Inoue S, Nishiwada T, et al. Effects of anesthetics on early postoperative cognitive outcome and intraoperative cerebral oxygen balance in patients undergoing lung surgery: A randomized clinical trial. Can J Anaesth. 2016;63(10):1161-1169. doi:10.1007/s12630-016-0700-4 10.1007/s12630-016-0700-4. Epub 2016 Jul 13.\n\n\n30. Epple J, Kubitz J, Schmidt H, et al. Comparative analysis of costs of total intravenous anaesthesia with propofol and remifentanil vs. Balanced anaesthesia with isoflurane and fentanyl. Eur J Anaesthesiol. 2001;18(1):20-28. doi:10.1046/j.1365-2346.2001.00764.x 10.1046/j.1365-2346.2001.00764.x.\n\n\n31. Ernst KF, Hall DE, Schmid KK, et al. Surgical palliative care consultations over time in relationship to systemwide frailty screening. JAMA Surg. 2014;149(11):1121-1126. doi:10.1001/jamasurg.2014.1393\n\n\n32. Fan GF, Hu Y, Zhang J, Chen L, He WS. Effect of dexmedetomidine on the postoperative cognitive function of patients undergoing radical resection of esophageal cancer. Biomedical Research (India). 2017;28(18):7977-7980. https://www.embase.com/search/results?subaction=viewrecord&id=L618931777&from=export\n\n\n33. Fan Y, Yuan L, Ji M, Yang J, Gao D. The effect of melatonin on early postoperative cognitive decline in elderly patients undergoing hip arthroplasty: A randomized controlled trial. J Clin Anesth. 2017;39:77-81. doi:10.1016/j.jclinane.2017.03.023\n\n\n34. Fazel MR, Kheirkhah P, Atoof F. Sevoflurane versus propofol anesthesia on early postoperative cognitive function in older adults: A randomized controlled trial. Middle East Journal of Anesthesiology. 2017;24(3):237-241. https://www.scopus.com/inward/record.uri?eid=2-s2.0-85044359450&partnerID=40&md5=02bec86eb3177f36f760ecb5b5b1d42d\n\n\n35. Forsmo HM, Pfeffer F, Rasdal A, et al. Compliance with enhanced recovery after surgery criteria and preoperative and postoperative counselling reduces length of hospital stay in colorectal surgery: Results of a randomized controlled trial. Colorectal Dis. 2022;18(6):603-611. doi:10.1111/codi.13253\n\n\n36. Fukata S, Kawabata Y, Fujishiro K, et al. Haloperidol prophylaxis for preventing aggravation of postoperative delirium in elderly patients: A randomized, open-label prospective trial. Surg Today. 2022;47(7):815-826. doi:10.1007/s00595-016-1441-2\n\n\n37. Fukata S, Kawabata Y, Fujisiro K, et al. Haloperidol prophylaxis does not prevent postoperative delirium in elderly patients: A randomized, open-label prospective trial. Surg Today. 2022;44(12):2305-2313. doi:10.1007/s00595-014-0859-7\n\n\n38. Gao Y, Yu H, Wang W, Wang Y, Teng J, Li F. Effect of dexmedetomidine on the neuroglobin expression in elderly patients with minimally invasive coronary artery bypass graft surgery. Heart Surg Forum. 2021;24(5):E776-e780. doi:10.1532/hsf.4073\n\n\n39. Gao Y, Zhu X, Huang L, Teng J, Li F. Effects of dexmedetomidine on cerebral oxygen saturation and postoperative cognitive function in elderly patients undergoing minimally invasive coronary artery bypass surgery. Clin Hemorheol Microcirc. 2020;74(4):383-389. doi:10.3233/ch-190590\n\n\n40. Ge YL, Li X, Gao J, et al. Beneficial effects of intravenous dexmedetomidine on cognitive function and cerebral injury following a carotid endarterectomy. Experimental and Therapeutic Medicine. 2016;11(3):1128-1134. doi:10.3892/etm.2016.2978\n\n\n41. Geng YJ, Wu QH, Zhang RQ. Effect of propofol, sevoflurane, and isoflurane on postoperative cognitive dysfunction following laparoscopic cholecystectomy in elderly patients: A randomized controlled trial. J Clin Anesth. 2017;38:165-171. doi:10.1016/j.jclinane.2017.02.007 10.1016/j.jclinane.2017.02.007. Epub 2017 Feb 20.\n\n\n42. Glumac S, Kardum G, Sodic L, et al. Longitudinal assessment of preoperative dexamethasone administration on cognitive function after cardiac surgery: A 4-year follow-up of a randomized controlled trial. BMC Anesthesiol. 2022;21(1):129. doi:10.1186/s12871-021-01348-z\n\n\n43. Glumac S, Kardum G, Sodic L, Supe-Domic D, Karanovic N. Effects of dexamethasone on early cognitive decline after cardiac surgery: A randomised controlled trial. Eur J Anaesthesiol. 2017;34(11):776-784. doi:10.1097/eja.0000000000000647\n\n\n44. Goins AE, Smeltz A, Ramm C, et al. General anesthesia for transcatheter aortic valve replacement: Total intravenous anesthesia is associated with less delirium as compared to volatile agent technique. J Cardiothorac Vasc Anesth. 2018;32(4):1570-1577. doi:10.1053/j.jvca.2017.12.018\n\n\n45. Guo Y, Sun L, Zhang J, Li Q, Jiang H, Jiang W. Preventive effects of low-dose dexmedetomidine on postoperative cognitive function and recovery quality in elderly oral cancer patients. Int J Clin Exp Med. 2015;8(9):16183-16190.\n\n\n46. Gupta PK, Verma R, Kohli M, Shukla N, Kannaujia S. The effect of ramelteon on postoperative delirium in elderly patients: A randomised double-blind study. Journal of Clinical and Diagnostic Research. 2019;13(12):UC15-UC19. doi:10.7860/JCDR/2019/42635.13384\n\n\n47. Hakim SM, Othman AI, Naoum DO. Early treatment with risperidone for subsyndromal delirium after on-pump cardiac surgery in the elderly: A randomized trial. Anesthesiology. 2012;116(5):987-997. doi:10.1097/ALN.0b013e31825153cc\n\n\n48. Hall DE, Arya S, Schmid KK, et al. Association of a frailty screening initiative with postoperative survival at 30, 180, and 365 days. JAMA Surg. 2017;152(3):233-240. doi:10.1001/jamasurg.2016.4219\n\n\n49. He F, Shen L, Zhong J. A study of dexmedetomidine in the prevention of postoperative delirium in elderly patients after vertebral osteotomy. International Journal of Clinical and Experimental Medicine. 2018;11(5):4984-4990. https://www.embase.com/search/results?subaction=viewrecord&id=L622367989&from=export\n\n\n50. Heilmann C, Stotz U, Burbaum C, et al. Short-term intervention to reduce anxiety before coronary artery bypass surgery–a randomised controlled trial. J Clin Nurs. 2022;25(3-4):351-361. doi:10.1111/jocn.13055\n\n\n51. Hempenius L, Slaets JP, Asselt D van, Bock GH e, Wiggers T, Leeuwen BL van. Outcomes of a geriatric liaison intervention to prevent the development of postoperative delirium in frail elderly cancer patients: Report on a multicentre, randomized, controlled trial. PLoS One. 2013;8(6):e64834. doi:10.1371/journal.pone.0064834\n\n\n52. Hempenius L, Slaets JP, Asselt D van, Bock TH e, Wiggers T, Leeuwen BL van. Long term outcomes of a geriatric liaison intervention in frail elderly cancer patients. PLoS One. 2016;11(2):e0143364. doi:10.1371/journal.pone.0143364\n\n\n53. Hokuto D, Nomi T, Yoshikawa T, Matsuo Y, Kamitani N, Sho M. Preventative effects of ramelteon against postoperative delirium after elective liver resection. PLoS One. 2020;15(11):e0241673. doi:10.1371/journal.pone.0241673\n\n\n54. Hollinger A, Rüst CA, Riegger H, et al. Ketamine vs. Haloperidol for prevention of cognitive dysfunction and postoperative delirium: A phase IV multicentre randomised placebo-controlled double-blind clinical trial. J Clin Anesth. 2021;68:110099. doi:10.1016/j.jclinane.2020.110099\n\n\n55. Hong H, Zhang DZ, Li M, et al. Impact of dexmedetomidine supplemented analgesia on delirium in patients recovering from orthopedic surgery: A randomized controlled trial. BMC Anesthesiol. 2021;21(1):223. doi:10.1186/s12871-021-01441-3\n\n\n56. Hongyu X, Qingting W, Xiaoling S, Liwu Z, Ailing Y, Xin L. Penehyclidine hydrochloride on postoperatively cognitive function. Med Hypotheses. 2019;129:109246. doi:10.1016/j.mehy.2019.109246\n\n\n57. Hu J, Zhu M, Gao Z, et al. Dexmedetomidine for prevention of postoperative delirium in older adults undergoing oesophagectomy with total intravenous anaesthesia: A double-blind, randomised clinical trial. Eur J Anaesthesiol. 2021;38(Suppl 1):S9-s17. doi:10.1097/eja.0000000000001382\n\n\n58. Hudetz JA, Iqbal Z, Gandhi SD, et al. Ketamine attenuates post-operative cognitive dysfunction after cardiac surgery. Acta Anaesthesiol Scand. 2009;53(7):864-872. doi:10.1111/j.1399-6576.2009.01978.x\n\n\n59. Hudetz JA, Patterson KM, Iqbal Z, et al. Ketamine attenuates delirium after cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2009;23(5):651-657. doi:10.1053/j.jvca.2008.12.021\n\n\n60. Huyan T, Hu X, Peng H, Zhu Z, Li Q, Zhang W. Perioperative dexmedetomidine reduces delirium in elderly patients after lung cancer surgery. Psychiatr Danub. 2019;31(1):95-101. doi:10.24869/psyd.2019.95\n\n\n61. Indrakusuma R, Dunker MS, Peetoom JJ, Schreurs WH. Evaluation of preoperative geriatric assessment of elderly patients with colorectal carcinoma. A retrospective study. Eur J Surg Oncol. 2015;41(1):21-27. doi:10.1016/j.ejso.2014.09.005\n\n\n62. Jakobsen CJ, Berg H, Hindsholm KB, Faddy N, Sloth E. The influence of propofol versus sevoflurane anesthesia on outcome in 10,535 cardiac surgical procedures. J Cardiothorac Vasc Anesth. 2007;21(5):664-671. doi:10.1053/j.jvca.2007.03.002\n\n\n63. Javaherforoosh Zadeh F, Janatmakan F, Shafaeebejestan E, Jorairahmadi S. Effect of melatonin on delirium after on-pump coronary artery bypass graft surgery: A randomized clinical trial. Iran J Med Sci. 2022;46(2):120-127. doi:10.30476/ijms.2020.82860.1146\n\n\n64. Jellish WS, Sheikh T, Baker WH, Louie EK, Slogoff S. Hemodynamic stability, myocardial ischemia, and perioperative outcome after carotid surgery with remifentanil/propofol or isoflurane/fentanyl anesthesia. J Neurosurg Anesthesiol. 2003;15(3):176-184. doi:10.1097/00008506-200307000-00004\n\n\n65. Jeong YM, Lee E, Kim KI, et al. Association of pre-operative medication use with post-operative delirium in surgical oncology patients receiving comprehensive geriatric assessment. BMC Geriatr. 2016;16:134. doi:10.1186/s12877-016-0311-5\n\n\n66. Kalisvaart KJ, Jonghe JF e, Bogaards MJ, et al. Haloperidol prophylaxis for elderly hip-surgery patients at risk for delirium: A randomized placebo-controlled study. J Am Geriatr Soc. 2022;53(10):1658-1666. doi:10.1111/j.1532-5415.2005.53503.x\n\n\n67. Kishimoto M, Yamana H, Inoue S, et al. Suspected periprosthetic joint infection after total knee arthroplasty under propofol versus sevoflurane anesthesia: A retrospective cohort study. Can J Anaesth. 2018;65(8):893-900. doi:10.1007/s12630-018-1139-6\n\n\n68. Konishi Y, Evered LA, Scott DA, Silbert BS. Postoperative cognitive dysfunction after sevoflurane or propofol general anaesthesia in combination with spinal anaesthesia for hip arthroplasty. Anaesth Intensive Care. 2018;46(6):596-600. doi:10.1177/0310057x1804600610\n\n\n69. Koo BW, Sim JB, Shin HJ, et al. Surgical site infection after colorectal surgery according to the main anesthetic agent: A retrospective comparison between volatile anesthetics and propofol. Korean J Anesthesiol. 2016;69(4):332-340. doi:10.4097/kjae.2016.69.4.332\n\n\n70. Kratz T, Heinrich M, Schlauß E, Diefenbacher A. Preventing postoperative delirium. Dtsch Arztebl Int. 2015;112(17):289-296. doi:10.3238/arztebl.2015.0289\n\n\n71. Larsen KA, Kelly SE, Stern TA, et al. Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: A randomized, controlled trial. Psychosomatics. 2022;51(5):409-418. doi:10.1176/appi.psy.51.5.409\n\n\n72. Lau TW, Fang C, Leung F. The effectiveness of a geriatric hip fracture clinical pathway in reducing hospital and rehabilitation length of stay and improving short-term mortality rates. Geriatr Orthop Surg Rehabil. 2022;4(1):3-9. doi:10.1177/2151458513484759\n\n\n73. Lee C, Lee CH, Lee G, Lee M, Hwang J. The effect of the timing and dose of dexmedetomidine on postoperative delirium in elderly patients after laparoscopic major non-cardiac surgery: A double blind randomized controlled study. J Clin Anesth. 2018;47:27-32. doi:10.1016/j.jclinane.2018.03.007\n\n\n74. Lee C, Lee J, Lee G, Lee H, Koh E, Hwang J. Pregabalin and dexmedetomidine combined for pain after total knee arthroplasty or total hip arthroplasty performed under spinal anesthesia. Orthopedics. 2018;41(6):365-370. doi:10.3928/01477447-20181023-04\n\n\n75. Lee KH, Kim JY, Kim JW, Park JS, Lee KW, Jeon SY. Influence of ketamine on early postoperative cognitive function after orthopedic surgery in elderly patients. Anesth Pain Med. 2015;5(5):e28844. doi:10.5812/aapm.28844\n\n\n76. Lester PE, Ripley D, Grandelli R, Drew LA, Keegan M, Islam S. Interdisciplinary protocol for surgery in older persons: Development and implementation. J Am Med Dir Assoc. 2022;23(4):555-562. doi:10.1016/j.jamda.2022.01.070\n\n\n77. Li WX, Luo RY, Chen C, et al. Effects of propofol, dexmedetomidine, and midazolam on postoperative cognitive dysfunction in elderly patients: A randomized controlled preliminary trial. Chin Med J (Engl). 2019;132(4):437-445. doi:10.1097/cm9.0000000000000098\n\n\n78. Li X, Yang J, Nie XL, et al. Impact of dexmedetomidine on the incidence of delirium in elderly patients after cardiac surgery: A randomized controlled trial. PLoS One. 2017;12(2):e0170757. doi:10.1371/journal.pone.0170757\n\n\n79. Li Y, Chen D, Wang H, et al. Intravenous versus volatile anesthetic effects on postoperative cognition in elderly patients undergoing laparoscopic abdominal surgery. Anesthesiology. 2021;134(3):381-394. doi:10.1097/aln.0000000000003680\n\n\n80. Li Y, He R, Chen S, Qu Y. Effect of dexmedetomidine on early postoperative cognitive dysfunction and peri-operative inflammation in elderly patients undergoing laparoscopic cholecystectomy. Exp Ther Med. 2015;10(5):1635-1642. doi:10.3892/etm.2015.2726\n\n\n81. Li Y, Wang C, Bi M, Gao J, Zhang X, Tian H. Effect of dexmedetomidine on brain function and hemodynamics in patients undergoing lung cancer resection. Oncology Letters. 2020;20(2):1077-1082. doi:10.3892/ol.2020.11675\n\n\n82. Li Z, Yao S, Cheng M, Chen J. Evaluation of the effect of dexmedetomidine on postoperative cognitive dysfunction through aβand cytokines analysis. Iran J Pharm Res. 2021;20(2):515-522. doi:10.22037/ijpr.2020.113576.14381\n\n\n83. Lindholm EE, Aune E, Norén CB, et al. The anesthesia in abdominal aortic surgery (ABSENT) study: A prospective, randomized, controlled trial comparing troponin t release with fentanyl-sevoflurane and propofol-remifentanil anesthesia in major vascular surgery. Anesthesiology. 2013;119(4):802-812. doi:10.1097/ALN.0b013e31829bd883\n\n\n84. Liu Y, Ma L, Gao M, Guo W, Ma Y. Dexmedetomidine reduces postoperative delirium after joint replacement in elderly patients with mild cognitive impairment. Aging Clin Exp Res. 2016;28(4):729-736. doi:10.1007/s40520-015-0492-3\n\n\n85. Lu J, Chen G, Zhou H, Zhou Q, Zhu Z, Wu C. Effect of parecoxib sodium pretreatment combined with dexmedetomidine on early postoperative cognitive dysfunction in elderly patients after shoulder arthroscopy: A randomized double blinded controlled trial. J Clin Anesth. 2017;41:30-34. doi:10.1016/j.jclinane.2017.06.004\n\n\n86. Lu Y, Fang PP, Yu YQ, et al. Effect of intraoperative dexmedetomidine on recovery of gastrointestinal function after abdominal surgery in older adults: A randomized clinical trial. JAMA Netw Open. 2022;4(10):e2128886. doi:10.1001/jamanetworkopen.2021.28886\n\n\n87. Mahrose R, ElSerwi H, Maurice A, Elsersi M. Postoperative delirium after coronary artery bypass graft surgery: Dexmedetomidine infusion alone or with the addition of oral melatonin. Egyptian Journal of Anaesthesia. 2021;37(1):62-68. doi:10.1080/11101849.2021.1885956\n\n\n88. Mangusan RF, Hooper V, Denslow SA, Travis L. Outcomes associated with postoperative delirium after cardiac surgery. Am J Crit Care. 2015;24(2):156-163. doi:10.4037/ajcc2015137\n\n\n89. Mansouri N, Nasrollahi K, Shetabi H. Prevention of cognitive dysfunction after cataract surgery with intravenous administration of midazolam and dexmedetomidine in elderly patients undergoing cataract surgery. Adv Biomed Res. 2019;8:6. doi:10.4103/abr.abr{\\_}190{\\_}18\n\n\n90. Marcantonio ER, Flacker JM, Wright RJ, Resnick NM. Reducing delirium after hip fracture: A randomized trial. J Am Geriatr Soc. 2001;49(5):516-522. doi:10.1046/j.1532-5415.2001.49108.x\n\n\n91. Mardani D, Bigdelian H. Prophylaxis of dexamethasone protects patients from further post-operative delirium after cardiac surgery: A randomized trial. Journal of Research in Medical Sciences. 2013;18(2):137-143. https://www.embase.com/search/results?subaction=viewrecord&id=L368561947&from=export\n\n\n92. Mei B, Meng G, Xu G, et al. Intraoperative sedation with dexmedetomidine is superior to propofol for elderly patients undergoing hip arthroplasty: A prospective randomized controlled study. Clin J Pain. 2018;34(9):811-817. doi:10.1097/ajp.0000000000000605\n\n\n93. Mei B, Xu G, Han W, et al. The benefit of dexmedetomidine on postoperative cognitive function is unrelated to the modulation on peripheral inflammation: A single-center, prospective, randomized study. Clin J Pain. 2020;36(2):88-95. doi:10.1097/ajp.0000000000000779\n\n\n94. Miyata R, Omasa M, Fujimoto R, Ishikawa H, Aoki M. Efficacy of ramelteon for delirium after lung cancer surgery. Interact Cardiovasc Thorac Surg. 2017;24(1):8-12. doi:10.1093/icvts/ivw297\n\n\n95. Mohamed S, Shaaban AR. The effect of dexmedetomidine on the incidence of postoperative cognitive dysfunction in elderly patients after prolonged abdominal surgery. Egyptian Journal of Anaesthesia. 2014;30(4):331-338. doi:10.1016/j.egja.2014.03.007\n\n\n96. Momeni M, Khalifa C, Lemaire G, et al. Propofol plus low-dose dexmedetomidine infusion and postoperative delirium in older patients undergoing cardiac surgery. Br J Anaesth. 2021;126(3):665-673. doi:10.1016/j.bja.2020.10.041\n\n\n97. Nandi S, Harvey WF, Saillant J, Kazakin A, Talmo C, Bono J. Pharmacologic risk factors for post-operative delirium in total joint arthroplasty patients: A case-control study. J Arthroplasty. 2022;29(2):268-271. doi:10.1016/j.arth.2013.06.004\n\n\n98. Nishikawa K, Nakayama M, Omote K, Namiki A. Recovery characteristics and post-operative delirium after long-duration laparoscope-assisted surgery in elderly patients: Propofol-based vs. Sevoflurane-based anesthesia. Acta Anaesthesiol Scand. 2004;48(2):162-168. doi:10.1111/j.0001-5172.2004.00264.x\n\n\n99. Oh TK, Kim J, Han S, Kim K, Jheon S, Ji E. Effect of sevoflurane-based or propofol-based anaesthesia on the incidence of postoperative acute kidney injury: A retrospective propensity score-matched analysis. Eur J Anaesthesiol. 2019;36(9):649-655. doi:10.1097/eja.0000000000001020\n\n\n100. Ommundsen N, Wyller TB, Nesbakken A, et al. Preoperative geriatric assessment and tailored interventions in frail older patients with colorectal cancer: A randomized controlled trial. Colorectal Dis. 2018;20(1):16-25. doi:10.1111/codi.13785\n\n\n101. Ottens TH, Dieleman JM, Sauer AM, et al. Effects of dexamethasone on cognitive decline after cardiac surgery: A randomized clinical trial. Anesthesiology. 2022;121(3):492-500. doi:10.1097/ALN.0000000000000336\n\n\n102. Özer E, Yilmaz R. Effect of different anesthetic techniques on mental outcome in elderly patients undergoing off-pump coronary artery bypass graft surgery. Turkiye Klinikleri Cardiovascular Sciences. 2017;29(1):17-22. doi:10.5336/cardiosci.2017-55853\n\n\n103. Palmbergen WA, Sonderen A van, Keyhan-Falsafi AM, Keunen RW, Wolterbeek R. Improved perioperative neurological monitoring of coronary artery bypass graft patients reduces the incidence of postoperative delirium: The haga brain care strategy. Interact Cardiovasc Thorac Surg. 2012;15(4):671-677. doi:10.1093/icvts/ivs317\n\n\n104. Park J, Lee SH, Lee JH, et al. Volatile versus total intravenous anesthesia for 30-day mortality following non-cardiac surgery in patients with preoperative myocardial injury. PLoS One. 2020;15(9):e0238661. doi:10.1371/journal.pone.0238661\n\n\n105. Partridge JS, Harari D, Martin FC, et al. Randomized clinical trial of comprehensive geriatric assessment and optimization in vascular surgery. Br J Surg. 2017;104(6):679-687. doi:10.1002/bjs.10459 10.1002/bjs.10459. Epub 2017 Feb 15.\n\n\n106. Prestmo A, Hagen G, Sletvold O, et al. Comprehensive geriatric care for patients with hip fractures: A prospective, randomised, controlled trial. Lancet. 2015;385(9978):1623-1633. doi:10.1016/s0140-6736(14)62409-0 10.1016/S0140-6736(14)62409-0. Epub 2015 Feb 5.\n\n\n107. Qiao H, Chen J, Huang Y, et al. Early neurocognitive function with propofol or desflurane anesthesia after laser laryngeal surgery with low inspired oxygen. Laryngoscope. Published online 2022. doi:10.1002/lary.30273\n\n\n108. Qiao Y, Feng H, Zhao T, Yan H, Zhang H, Zhao X. Postoperative cognitive dysfunction after inhalational anesthesia in elderly patients undergoing major surgery: The influence of anesthetic technique, cerebral injury and systemic inflammation. BMC Anesthesiol. 2015;15:154. doi:10.1186/s12871-015-0130-9\n\n\n109. Qin Y, Ni J, Kang L, Zhong Z, Wang L, Yin S. Sevoflurane effect on cognitive function and the expression of oxidative stress response proteins in elderly patients undergoing radical surgery for lung cancer. J Coll Physicians Surg Pak. 2019;29(1):12-15. doi:10.29271/jcpsp.2019.01.12\n\n\n110. Rascón-Martı́nez DM, Fresán-Orellana A, Ocharán-Hernández ME, Genis-Zarate JH, Castellanos-Olivares A. The effects of ketamine on cognitive function in elderly patients undergoing ophthalmic surgery: A pilot study. Anesth Analg. 2016;122(4):969-975. doi:10.1213/ane.0000000000001153\n\n\n111. Richter HE, Redden DT, Duxbury AS, Granieri EC, Halli AD, Goode PS. Pelvic floor surgery in the older woman: Enhanced compared with usual preoperative assessment. Obstet Gynecol. 2005;105(4):800-807. doi:10.1097/01.Aog.0000154920.12402.02\n\n\n112. Rohan D, Buggy DJ, Crowley S, et al. Increased incidence of postoperative cognitive dysfunction 24 hr after minor surgery in the elderly. Can J Anaesth. 2005;52(2):137-142. doi:10.1007/bf03027718\n\n\n113. Romano LU, Rigoni M, Torri E, et al. A propensity score-matched analysis to assess the outcomes in pre-and post-fast-track hip and knee elective prosthesis patients. Journal of Clinical Medicine. 2021;10(4):1-13. doi:10.3390/jcm10040741\n\n\n114. Royse CF, Saager L, Whitlock R, et al. Impact of methylprednisolone on postoperative quality of recovery and delirium in the steroids in cardiac surgery trial: A randomized, double-blind, placebo-controlled substudy. Anesthesiology. 2017;126(2):223-233. doi:10.1097/aln.0000000000001433\n\n\n115. Šakić L, Tonković D, Godan BJ, Šakić K. The influence of dexamethasone administration in spinal anesthesia for femur fracture on postoperative cognitive dysfunction. Periodicum Biologorum. 2015;117(2):281-285. https://www.embase.com/search/results?subaction=viewrecord&id=L605675897&from=export\n\n\n116. Sauer AM, Slooter AJ, Veldhuijzen DS, Eijk MM van, Devlin JW, Dijk D van. Intraoperative dexamethasone and delirium after cardiac surgery: A randomized clinical trial. Anesth Analg. 2022;119(5):1046-1052. doi:10.1213/ANE.0000000000000248\n\n\n117. Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: A randomized controlled trial (DEXmedetomidine COmpared to morphine-DEXCOM study). Anesthesiology. 2009;111(5):1075-1084. doi:10.1097/ALN.0b013e3181b6a783\n\n\n118. Shem Tov L, Matot I. Frailty and anesthesia. Curr Opin Anaesthesiol. 2017;30(3):409-417. doi:10.1097/aco.0000000000000456\n\n\n119. Shi C, Jin J, Qiao L, Li T, Ma J, Ma Z. Effect of perioperative administration of dexmedetomidine on delirium after cardiac surgery in elderly patients: A double-blinded, multi-center, randomized study. Clin Interv Aging. 2019;14:571-575. doi:10.2147/cia.S194476\n\n\n120. Shi H, Du X, Wu F, Hu Y, Xv Z, Mi W. Dexmedetomidine improves early postoperative neurocognitive disorder in elderly male patients undergoing thoracoscopic lobectomy. Exp Ther Med. 2020;20(4):3868-3877. doi:10.3892/etm.2020.9113\n\n\n121. Shi Y. Effects of melatonin on postoperative delirium after PCI in elderly patients: A randomized, single-center, double-blind, placebo-controlled trial. Heart Surg Forum. 2022;24(5):E893-E897. doi:10.1532/hsf.4049\n\n\n122. Shimizu K, Hirose M, Mikami S, et al. Effect of anaesthesia maintained with sevoflurane and propofol on surgical site infection after elective open gastrointestinal surgery. J Hosp Infect. 2010;74(2):129-136. doi:10.1016/j.jhin.2009.10.011\n\n\n123. Shin HJ, Choi SL, Na HS. Prevalence of postoperative delirium with different combinations of intraoperative general anesthetic agents in patients undergoing cardiac surgery: A retrospective propensity-score-matched study. Medicine (Baltimore). 2021;100(33):e26992. doi:10.1097/md.0000000000026992\n\n\n124. Siripoonyothai S, Sindhvananda W. Comparison of postoperative delirium within 24 hours between ketamine and propofol infusion during cardiopulmonary bypass machine: A randomized controlled trial. Ann Card Anaesth. 2021;24(3):294-301. doi:10.4103/aca.ACA{\\_}85{\\_}20\n\n\n125. Slor CJ, Jonghe JF e, Vreeswijk R, et al. Anesthesia and postoperative delirium in older adults undergoing hip surgery. J Am Geriatr Soc. 2011;59(7):1313-1319. doi:10.1111/j.1532-5415.2011.03452.x\n\n\n126. Souwer ETD, Bastiaannet E, Bruijn S e, et al. Comprehensive multidisciplinary care program for elderly colorectal cancer patients: \"From prehabilitation to independence\". Eur J Surg Oncol. 2018;44(12):1894-1900. doi:10.1016/j.ejso.2018.08.028\n\n\n127. Su X, Meng ZT, Wu XH, et al. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: A randomised, double-blind, placebo-controlled trial. Lancet. 2016;388(10054):1893-1902. doi:10.1016/s0140-6736(16)30580-3\n\n\n128. Subramaniam B, Shankar P, Shaefi S, et al. Effect of intravenous acetaminophen vs placebo combined with propofol or dexmedetomidine on postoperative delirium among older patients following cardiac surgery: The DEXACET randomized clinical trial. Jama. 2019;321(7):686-696. doi:10.1001/jama.2019.0234\n\n\n129. Sultan SS. Assessment of role of perioperative melatonin in prevention and treatment of postoperative delirium after hip arthroplasty under spinal anesthesia in the elderly. Saudi J Anaesth. 2010;4(3):169-173. doi:10.4103/1658-354x.71132\n\n\n130. Sun M, Peng T, Sun Y, et al. Intraoperative use of low-dose dexmedetomidine for the prevention of emergence agitation following general anaesthesia in elderly patients: A randomized controlled trial. Aging Clin Exp Res. 2022;34(3):611-618. doi:10.1007/s40520-021-01984-y\n\n\n131. Sun Y, Jiang M, Ji Y, Sun Y, Liu Y, Shen W. Impact of postoperative dexmedetomidine infusion on incidence of delirium in elderly patients undergoing major elective noncardiac surgery: A randomized clinical trial. Drug Des Devel Ther. 2019;13:2911-2922. doi:10.2147/dddt.S208703\n\n\n132. Tan Y, Ouyang W, Tang Y, Fang N, Fang C, Quan C. Effect of remimazolam tosilate on early cognitive function in elderly patients undergoing upper gastrointestinal endoscopy. J Gastroenterol Hepatol. 2022;37(3):576-583. doi:10.1111/jgh.15761\n\n\n133. Tanaka P, Goodman S, Sommer BR, Maloney W, Huddleston J, Lemmens HJ. The effect of desflurane versus propofol anesthesia on postoperative delirium in elderly obese patients undergoing total knee replacement: A randomized, controlled, double-blinded clinical trial. J Clin Anesth. 2017;39:17-22. doi:10.1016/j.jclinane.2017.03.015\n\n\n134. Tang N, Ou C, Liu Y, Zuo Y, Bai Y. Effect of inhalational anaesthetic on postoperative cognitive dysfunction following radical rectal resection in elderly patients with mild cognitive impairment. J Int Med Res. 2014;42(6):1252-1261. doi:10.1177/0300060514549781 10.1177/0300060514549781. Epub 2014 Oct 22.\n\n\n135. Tang Y, Liu J, Huang X, Ding H, Tan S, Zhu Y. Effect of dexmedetomidine-assisted intravenous inhalation combined anesthesia on cerebral oxygen metabolism and serum Th1/Th2 level in elderly colorectal cancer patients. Front Surg. 2022;8:832646. doi:10.3389/fsurg.2021.832646\n\n\n136. Tu W, Yuan H, Zhang S, et al. Influence of anesthetic induction of propofol combined with esketamine on perioperative stress and inflammatory responses and postoperative cognition of elderly surgical patients. American Journal of Translational Research. 2021;13(3):1701-1709. https://www.embase.com/search/results?subaction=viewrecord&id=L2011456630&from=export\n\n\n137. Turan A, Duncan A, Leung S, et al. Dexmedetomidine for reduction of atrial fibrillation and delirium after cardiac surgery (DECADE): A randomised placebo-controlled trial. Lancet. 2020;396(10245):177-185. doi:10.1016/S0140-6736(20)30631-0\n\n\n138. Ushida T, Yokoyama T, Kishida Y, et al. Incidence and risk factors of postoperative delirium in cervical spine surgery. Spine (Phila Pa 1976). 2022;34(23):2500-2504. doi:10.1097/BRS.0b013e3181b321e6\n\n\n139. Vlies E van der, Smits AB, Los M, et al. Implementation of a preoperative multidisciplinary team approach for frail colorectal cancer patients: Influence on patient selection, prehabilitation and outcome. J Geriatr Oncol. 2020;11(8):1237-1243. doi:10.1016/j.jgo.2020.04.011\n\n\n140. Norden J van, Spies CD, Borchers F, et al. The effect of peri-operative dexmedetomidine on the incidence of postoperative delirium in cardiac and non-cardiac surgical patients: A randomised, double-blind placebo-controlled trial. Anaesthesia. 2021;76(10):1342-1351. doi:10.1111/anae.15469\n\n\n141. Vidán M, Serra JA, Moreno C, Riquelme G, Ortiz J. Efficacy of a comprehensive geriatric intervention in older patients hospitalized for hip fracture: A randomized, controlled trial. J Am Geriatr Soc. 2005;53(9):1476-1482. doi:10.1111/j.1532-5415.2005.53466.x 10.1111/j.1532-5415.2005.53466.x.\n\n\n142. Vochteloo AJ, Moerman S, Burg BL van der, et al. Delirium risk screening and haloperidol prophylaxis program in hip fracture patients is a helpful tool in identifying high-risk patients, but does not reduce the incidence of delirium. BMC Geriatr. 2011;11:39. doi:10.1186/1471-2318-11-39 10.1186/1471-2318-11-39.\n\n\n143. Wang F, Xie D, Xu H, Ye Q, Wu L, Gao XP. The effects of remifentanil-propofol combined with dexmedetomidine on cognitive dysfunction in elderly patients after ureteroscopic holmium laser lithotripsy: A double-blind randomized controlled trial. Trials. 2022;23(1):192. doi:10.1186/s13063-022-06121-2\n\n\n144. Wang L, Zhang T, Huang L, Peng W. Comparison between dexmedetomidine and midazolam for sedation in patients with intubation after oral and maxillofacial surgery. Biomed Res Int. 2020;2020:7082597. doi:10.1155/2020/7082597\n\n\n145. Wang ML, Min J, Sands LP, Leung JM. Midazolam premedication immediately before surgery is not associated with early postoperative delirium. Anesth Analg. 2021;133(3):765-771. doi:10.1213/ane.0000000000005482\n\n\n146. Wang W, Feng N, Zhao W, et al. Dexmedetomidine reduces brain neuronal injuries but not clinical neurocognitive function in the elderly, compared to midazolam. International Journal of Clinical and Experimental Medicine. 2019;12(4):4210-4217. https://www.embase.com/search/results?subaction=viewrecord&id=L2001919677&from=export\n\n\n147. Wang W, Li HL, Wang DX, et al. Haloperidol prophylaxis decreases delirium incidence in elderly patients after noncardiac surgery: A randomized controlled trial*. Crit Care Med. 2022;40(3):731-739. doi:10.1097/CCM.0b013e3182376e4f\n\n\n148. Wang Z, Shen Z, Wang H, Zhang L, Dong R. Effect of dexmedetomidine on the cognitive function of patients undergoing gastric cancer surgery by regulating the PI3K/AKT signaling pathway. Oncology Letters. 2020;19(2):1151-1156. doi:10.3892/ol.2019.11224\n\n\n149. Watne LO, Torbergsen AC, Conroy S, et al. The effect of a pre- and postoperative orthogeriatric service on cognitive function in patients with hip fracture: Randomized controlled trial (oslo orthogeriatric trial). BMC Med. 2014;12:63. doi:10.1186/1741-7015-12-63\n\n\n150. Weaver FM, Hughes SL, Almagor O, et al. Comparison of two home care protocols for total joint replacement. J Am Geriatr Soc. 2003;51(4):523-528. doi:10.1046/j.1532-5415.2003.51162.x\n\n\n151. Whitlock RP, Devereaux PJ, Teoh KH, et al. Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): A randomised, double-blind, placebo-controlled trial. Lancet. 2022;386(10000):1243-1253. doi:10.1016/S0140-6736(15)00273-1\n\n\n152. Wu LP, Kang WQ. Effect of dexmedetomidine for sedation and cognitive function in patients with preoperative anxiety undergoing carotid artery stenting. J Int Med Res. 2020;48(9):300060520938959. doi:10.1177/0300060520938959\n\n\n153. Wu ZF, Lee MS, Wong CS, et al. Propofol-based total intravenous anesthesia is associated with better survival than desflurane anesthesia in colon cancer surgery. Anesthesiology. 2018;129(5):932-941. doi:10.1097/aln.0000000000002357\n\n\n154. Xiang XB, Chen H, Wu YL, Wang K, Yue X, Cheng XQ. The effect of preoperative methylprednisolone on postoperative delirium in older patients undergoing gastrointestinal surgery: A randomized, double-blind, placebo-controlled trial. J Gerontol A Biol Sci Med Sci. 2022;77(3):517-523. doi:10.1093/gerona/glab248\n\n\n155. Xin X, Chen J, Hua W, Wang H. Intraoperative dexmedetomidine for prevention of postoperative delirium in elderly patients with mild cognitive impairment. Int J Geriatr Psychiatry. 2021;36(1):143-151. doi:10.1002/gps.5406\n\n\n156. Xing C, Yan C. Effects of dexmedetomidine on the incidence of postoperative delirium and plasma s-100βprotein levels following hip surgery in the elderly population. International Journal of Gerontology. 2021;15(3):207-211. doi:10.6890/IJGE.202107{\\_}15(3).0004\n\n\n157. Xuan Y, Fan R, Chen J, et al. Effects of dexmedetomidine for postoperative delirium after joint replacement in elderly patients: A randomized, double-blind, and placebo-controlled trial. International Journal of Clinical and Experimental Medicine. 2018;11(12):13147-13157. https://www.embase.com/search/results?subaction=viewrecord&id=L625709588&from=export\n\n\n158. Yamasaki M, Fukuda Y, Tanimoto A, et al. Reduction in the rate of postoperative delirium by switching from famotidine to omeprazole in japanese hepatectomized recipients. J Pharm Health Care Sci. 2022;5:10. doi:10.1186/s40780-019-0139-1\n\n\n159. Yan C, Ti-jun D. Effects of intraoperative dexmedetomidine infusion on postoperative delirium in elderly patients undergoing total hip arthroplasty. International Surgery. 2021;105(1-3):328-335. doi:10.9738/intsurg-d-17-00029.1\n\n\n160. Yu DN, Zhu Y, Ma J, Sun Q. Comparison of post-anesthesia delirium in elderly patients treated with dexmedetomidine and midazolam maleate after thoracic surgery. Biomedical Research (India). 2017;28(15):6852-6855. https://www.embase.com/search/results?subaction=viewrecord&id=L618295307&from=export\n\n\n161. Zangrillo A, Testa V, Aldrovandi V, et al. Volatile agents for cardiac protection in noncardiac surgery: A randomized controlled study. J Cardiothorac Vasc Anesth. 2011;25(6):902-907. doi:10.1053/j.jvca.2011.06.016\n\n\n162. Zhang DF, Su X, Meng ZT, et al. Impact of dexmedetomidine on long-term outcomes after noncardiac surgery in elderly: 3-year follow-up of a randomized controlled trial. Ann Surg. 2019;270(2):356-363. doi:10.1097/sla.0000000000002801\n\n\n163. Zhang H, Wu Z, Zhao X, Qiao Y. Role of dexmedetomidine in reducing the incidence of postoperative cognitive dysfunction caused by sevoflurane inhalation anesthesia in elderly patients with esophageal carcinoma. J Cancer Res Ther. 2018;14(7):1497-1502. doi:10.4103/jcrt.JCRT{\\_}164{\\_}18\n\n\n164. Zhang W, Sun Y, Liu Y, et al. A nursing protocol targeting risk factors for reducing postoperative delirium in patients following coronary artery bypass grafting: Results of a prospective before-after study. Int J Nurs Sci. 2017;4(2):81-87. doi:10.1016/j.ijnss.2017.02.002\n\n\n165. Zhang W, Wang T, Wang G, Yang M, Zhou Y, Yuan Y. Effects of dexmedetomidine on postoperative delirium and expression of IL-1β, IL-6, and TNF-αin elderly patients after hip fracture operation. Front Pharmacol. 2020;11:678. doi:10.3389/fphar.2020.00678\n\n\n166. Zhang Y, Shan GJ, Zhang YX, et al. Propofol compared with sevoflurane general anaesthesia is associated with decreased delayed neurocognitive recovery in older adults. Br J Anaesth. 2018;121(3):595-604. doi:10.1016/j.bja.2018.05.059\n\n\n167. Zhang Z, Li W, Jia H. Postoperative effects of dexmedetomidine on serum inflammatory factors and cognitive malfunctioning in patients with general anesthesia. J Healthc Eng. 2021;2021:7161901. doi:10.1155/2021/7161901\n\n\n168. Zhao W, Hu Y, Chen H, et al. The effect and optimal dosage of dexmedetomidine plus sufentanil for postoperative analgesia in elderly patients with postoperative delirium and early postoperative cognitive dysfunction: A single-center, prospective, randomized, double-blind, controlled trial. Front Neurosci. 2020;14:549516. doi:10.3389/fnins.2020.549516\n\n\n169. Zhou M, Lyu Y, Zhu Y, et al. Effect of ulinastatin combined with dexmedetomidine on postoperative cognitive dysfunction in patients who underwent cardiac surgery. Frontiers in Neurology. 2019;10. doi:10.3389/fneur.2019.01293\n\n\n170. Zhou ZJ, Tang J, Li WH, Tao WD. Preoperative intravenous flurbiprofen reduces postoperative pain and inflammatory cytokines in elderly patients after hip arthroplasty. Exp Ther Med. 2019;17(1):354-358. doi:10.3892/etm.2018.6911\n\n\n171. Zhu Y, Le G. The effect of dexmedetomidine combined with epidural anesthesia on post-operative cognitive dysfunction in elderly patients after orthopedic surgery. Am J Transl Res. 2022;13(10):12058-12064. https://www.ncbi.nlm.nih.gov/pubmed/34786142\n\n\n172. Zhu Y, Yao R, Li Y, et al. Protective effect of celecoxib on early postoperative cognitive dysfunction in geriatric patients. Front Neurol. 2018;9:633. doi:10.3389/fneur.2018.00633"
  },
  {
    "objectID": "kq8.html",
    "href": "kq8.html",
    "title": "KQ 8 Delirium Screening",
    "section": "",
    "text": "Does screening patients 65 years or older [geriatric] for postoperative delirium in the post anesthesia care unit improve postoperative outcomes?"
  },
  {
    "objectID": "kq8.html#outcome-importance-rankings",
    "href": "kq8.html#outcome-importance-rankings",
    "title": "KQ 8 Delirium Screening",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Evidence Synthesis",
    "section": "",
    "text": "Draft materials. Not to be cited.\nCorrections, suggestions for additions, or comments can be sent to Mark Grant.\nThe current protocol can be found here.\nKQ1 Expanded Preoperative Screening\nKQ2 Prehabilitation\nKQ3 Regional vs. General Anesthesia\nKQ4 Intravenous vs. Inhaled Anesthesia\nKQ5 Potentially Inappropriate Medications\nKQ6 Delirium Prophylaxis\nKQ8 Delirium Screening"
  },
  {
    "objectID": "kq3.html",
    "href": "kq3.html",
    "title": "KQ 3 Regional vs. General Anesthesia",
    "section": "",
    "text": "Among patients 65 years or older [geriatric] undergoing surgery, does regional anesthesia as the primary anesthetic technique improve postoperative outcomes compared with general anesthesia?"
  },
  {
    "objectID": "kq3.html#outcome-importance-rankings",
    "href": "kq3.html#outcome-importance-rankings",
    "title": "KQ 3 Regional vs. General Anesthesia",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "About",
    "section": "",
    "text": "About this site\n\n1 + 1\n\n[1] 2"
  },
  {
    "objectID": "kq2.html",
    "href": "kq2.html",
    "title": "KQ 2 Prehabilitation",
    "section": "",
    "text": "Among patients 65 years or older [geriatric] anticipating surgery and anesthesia, do interventions targeted at improving physical function, cognition, and nutritional status before surgery (“prehabilitation”) improve postoperative outcomes?"
  },
  {
    "objectID": "kq2.html#outcome-importance-rankings",
    "href": "kq2.html#outcome-importance-rankings",
    "title": "KQ 2 Prehabilitation",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "kq1.html",
    "href": "kq1.html",
    "title": "KQ 1 Expanded Preoperative Screening",
    "section": "",
    "text": "Among patients 65 years or older [geriatric] anticipating surgery and anesthesia, does expanded preoperative evaluation (e.g., for frailty, cognitive impairment, functional status, or psychosocial issues) lead to improved postoperative outcomes?"
  },
  {
    "objectID": "kq1.html#outcome-importance-rankings",
    "href": "kq1.html#outcome-importance-rankings",
    "title": "KQ 1 Expanded Preoperative Screening",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "kq5.html",
    "href": "kq5.html",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "",
    "text": "Among patients 65 years or older [geriatric] undergoing surgery and anesthesia, do commonly used potentially inappropriate medications administered during the perioperative period increase the risk of postoperative delirium or other adverse outcomes?"
  },
  {
    "objectID": "kq5.html#outcome-importance-rankings",
    "href": "kq5.html#outcome-importance-rankings",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "kq5.html#causal-model",
    "href": "kq5.html#causal-model",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Causal Model",
    "text": "Causal Model\n Figure 1. Causal model for the relationship between potentially inappropriate medications and outcomes. Potential mediators include anesthetics, other drugs, pain, hypotension, clinical instability, infection, electrolytes, and sleep deprivation. \n\n\n\n\n\n PIM: potentially inappropriate medications."
  },
  {
    "objectID": "kq5.html#included-studies",
    "href": "kq5.html#included-studies",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Included Studies",
    "text": "Included Studies\n Table 2. Number of studies by design. \n\n\n\n\n\n\n\n  \n    \n    \n  \n  \n  \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n30\n    Before-After/Time Series\n2\n    Prospective Cohort\n3\n    Retrospective Cohort\n2\n    Case-Control\n2\n    Total\n39"
  },
  {
    "objectID": "kq5.html#design-centers-country-surgery",
    "href": "kq5.html#design-centers-country-surgery",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Design, centers, country, surgery",
    "text": "Design, centers, country, surgery\n Table 3. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n\n  \n  \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Drug Class\n      Surgeryb\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    1505\nHongyu 2019\n\n1\n90\nChinaa\nAnticholinergic\n\nThoracic\n    4824\nHakim 2012\n\n1\n101\nEgypta\nAntipsychotic\n\nCardiac\n    16607\nPrakanrattana 2007\n\n1\n126\nThailand\nAntipsychotic\n\nCardiac\n    1937\nHollinger 2021\n\n2\n200\nSwitzerland\nAntipsychotic\n\nCardiac|Gyn|Ortho|Thoracic|Vasc\n    7309\nFukata 2017\n\n3\n201\nJapan\nAntipsychotic\n\nGI/Abdominal|Hepatic|Ortho\n    9196\nWang 2012\n\n2\n457\nChinaa\nAntipsychotic\n\nGI/Abdominal|Neuro|Ortho|Thoracic\n    8864\nFukata 2014\n\n5\n121\nJapan\nAntipsychotic\n\nGI/Abdominal|Ortho\n    7098\nLarsen 2010\n\n1\n495\nUSA\nAntipsychotic\n\nOrtho\n    8574\nKalisvaart 2005\n\n1\n430\nNetherlands\nAntipsychotic\n\nOrtho\n    13579\nAzeem 2018\n\n1\n70\nEgypta\nBenzodiazepine\n\nCardiac\n    9157\nTan 2022\n\n1\n99\nChinaa\nBenzodiazepine\n\nGI/Abdominal\n    9620\nAizawa 2002\n\n1\n42\nJapan\nBenzodiazepine\n\nGI/Abdominal\n    1117\nMansouri 2019\n\n1\n150\nIrana\nBenzodiazepine\n\nOphtho\n    1625\nWang 2020\n\n1\n44\nChinaa\nBenzodiazepine\n\nOralmax\n    742\nLi 2019\n\n1\n164\nChinaa\nBenzodiazepine\n\nOrtho\n    5164\nSultan 2010\n\n1\n222\nEgypta\nBenzodiazepine\n\nOrtho\n    13568\nHe 2018\n\n1\n90\nChinaa\nBenzodiazepine\n\nThoracic\n    13731\nYu 2017\n\n1\n92\nChinaa\nBenzodiazepine\n\nThoracic\n    2778\nGlumac 2017\n\n1\n169\nCroatia\nCorticosteroid\n\nCardiac\n    3250\nRoyse 2017\n\n3\n555\nAustralia\nCorticosteroid\n\nCardiac\n    7758\nGlumac 2021\n\n1\n169\nCroatia\nCorticosteroid\n\nCardiac\n    10036\nSauer 2014\n\n1\n737\nNetherlands\nCorticosteroid\n\nCardiac\n    10075\nOttens 2014\n\n3\n291\nNetherlands\nCorticosteroid\n\nCardiac\n    10515\nWhitlock 2015\n\n80\n7507\nCanada\nCorticosteroid\n\nCardiac\n    14006\nMardani 2013\n\n1\n110\nIrana\nCorticosteroid\n\nCardiac\n    16533\nDieleman 2012\n\n8\n4494\nNetherlands\nCorticosteroid\n\nCardiac\n    7686\nXiang 2022\n\n1\n174\nChinaa\nCorticosteroid\n\nGI/Abdominal\n    13888\nŠakić 2015\n\n1\n60\nCroatia\nCorticosteroid\n\nOrtho\n    5765\nZhu 2018\n\n1\n178\nChinaa\nNSAID\n\nOrtho\n    5809\nZhou 2019\n\n1\n180\nChinaa\nNSAID\n\nOrtho\n    \n      Prospective Cohort\n    \n    7722\nDuprey 2022\n\n2\n566\nUSA\nAnticholinergic|Antipsychotic| Benzodiazepine|NSAID\n\nNon-cardiac\n    2338\nBickel 2008\n\n1\n200\nGermany\nAntipsychotic\n\nOrtho\n    1332\nWang 2021\n\n1\n1266\nTaiwana\nBenzodiazepine\n\nVarious\n    \n      Retrospective Cohort\n    \n    246\nJeong 2016\n\n1\n527\nSouth Korea\nAnticholinergic|H2 blocker| Benzodiazepine\n\nOther\n    3727\nMangusan 2015\n\n1\n656\nUSA\nNSAID|Benzodiazepine| Nonbenzodiazepine hypnotic\n\nCardiac\n    \n      Case-Control\n    \n    9279\nNandi 2014\n\n1\n463\nUSA\nBenzodiazepine\n\nOrtho\n    9977\nChoi 2019\n\n1\n58\nSouth Korea\nCorticosteroid\n\nThoracic\n    \n      Before-After/Time Series\n    \n    9464\nUshida 2009\n\n1\n122\nJapan\nCorticosteroid\n\nOrtho\n    10090\nYamasaki 2019\n\n1\n21\nJapan\nH2 blocker\n\nGI/Abdominal\n  \n  \n    \n      Antichol: anticholinergics; Antipsych: antipsychotics; GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n  \n  \n    \n      a Non very high Human Development Index country.\n    \n    \n      b Various indicates more than 4 different types of surgery."
  },
  {
    "objectID": "kq5.html#drugs-by-study",
    "href": "kq5.html#drugs-by-study",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Drugs by Study",
    "text": "Drugs by Study\n\n\n\n\nBenzodiazepines\n Table 4. Studies examining benzodiazepines, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n      Benzodiazepines\n    \n    \n  \n  \n    \n      Study\n      N\n      Drug\n      Dosing\n      Timing\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Li 2019\n\n55\nOther\n \n\n    \n55\nDexmedetomidine\n \n\n    \n54\nMidazolam\n \nIntraop\n    Mansouri 2019\n\n50\nPlacebo\n \n\n    \n50\nDexmedetomidine\n \n\n    \n50\nMidazolam\n0.1mg/kg (qd×1d)\nIntraop\n    Wang 2020\n\n20\nDexmedetomidine\n \n\n    \n20\nMidazolam\n0.04-0.02mg/kg (1d)\nIntraop\n    Sultan 2010\n\n49\nNone\n \n\n    \n53\nMelatonin\n \n\n    \n50\nMidazolam\n7.5mg (qd×2d)\nPreop\n    Tan 2022\n\n33\nPropofol\n \n\n    \n33\nRemimazolam\n0.2mg/kg (qd×1d)\nInduction|Intraop\n    \n33\nRemimazolam\n0.10mg/kg (qd×1d)\nInduction|Intraop\n    Aizawa 2002\n\n20\nNone\n \n\n    \n20\nDiazepam\n0.1mg/kg (qd×3d)\nPreop|Postop-prev\n    He 2018\n\n30\nPlacebo\n \n\n    \n30\nDexmedetomidine\n \n\n    \n30\nMidazolam\n0.03mg/kg (qd×1d)\nPreop\n    Azeem 2018\n\n30\nDexmedetomidine\n \n\n    \n30\nMidazolam\n0.05mg/kg \n\n    Yu 2017\n\n46\nDexmedetomidine\n \n\n    \n46\nMidazolam\n0.05ug/kg (bid×1d)\nPreop|Intraop\n    \n      Prospective Cohort\n    \n    Wang 2021\n\n357\nNone\n \n\n    \n357\nMidazolam\n \nPreop\n    Duprey 2022\n\n60\nAny benzodiazepine\nNR\nIntraop\n    \n      Case-Control\n    \n    Nandi 2014\n\n376\nNone\n \n\n    \n87\nAny benzodiazepine\n \nUnspecified\n  \n  \n    \n      Intraop: intraoperative; Preop:preopertive; Postop: postoperative; prev:preventive.\n    \n  \n  \n\n\n\n\n\n\n\nAntipsychotics\n Table 5. Studies examining antipsychotics, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n      Antipsychotics\n    \n    \n  \n  \n    \n      Study\n      N\n      Drug\n      Dosing\n      Timing\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Hollinger 2021\n\n44\nPlacebo\n \n\n    \n47\nKetamine\n \n\n    \n45\nHaloperidol\n5ug/kg (qd×1d)\nInduction\n    Hakim 2012\n\n50\nPlacebo\n \n\n    \n51\nRisperdone\n0.5mg (bid)\nPostop-treat\n    Larsen 2010\n\n204\nPlacebo\n \n\n    \n196\nOlanzapine\n5mg (bid×1d)\nPreop|Postop-prev\n    Fukata 2017\n\n100\nNone\n \n\n    \n99\nHaloperidol\n5mg (qd×6d)\nPostop-prev\n    Kalisvaart 2005\n\n218\nPlacebo\n \n\n    \n212\nHaloperidol\n0.5mg (tid×4-6d)\nPreop|Postop-prev\n    Fukata 2014\n\n60\nNone\n \n\n    \n59\nHaloperidol\n2.5mg (qd×3d)\nPostop-prev\n    Wang 2012\n\n228\nPlacebo\n \n\n    \n229\nHaloperidol\n5mg (qd×1d)\nPostop-prev\n    Prakanrattana 2007\n\n63\nPlacebo\n \n\n    \n63\nRisperdone\n1mg (qd×1d)\nPostop-prev\n    \n      Prospective Cohort\n    \n    Bickel 2008\n\n22\nAny antipsychotic\nNR\nPreop\n  \n  \n    \n      Preop:preopertive; Postop: postoperative; prev:preventive.\n    \n  \n  \n\n\n\n\n\n\n\nAnticholinergics\n Table 6. Studies examining anticholinergics, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n      Anticholinergics\n    \n    \n  \n  \n    \n      Study\n      N\n      Drug\n      Dosing\n      Timing\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Hongyu 2019\n\n30\nPlacebo\n \n\n    \n30\nPenehyclidine\n0.01mg/kg (qd×1d)\nPreop\n  \n  \n    \n      Preop:preopertive.\n    \n  \n  \n\n\n\n\n\n\n\nCorticosteroids\n Table 7. Studies examining corticosteroids, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n      Corticosteroids\n    \n    \n  \n  \n    \n      Study\n      N\n      Drug\n      Dosing\n      Timing\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Glumac 2017\n\n81\nPlacebo\n \n\n    \n80\nDexamethasone\n0.1mg/kg (qd×1d)\nPreop\n    Royse 2017\n\n246\nPlacebo\n \n\n    \n236\nMethylprednisolone\n250mg (bid×1d)\nInduction|Intraop\n    Xiang 2022\n\n84\nPlacebo\n \n\n    \n84\nMethylprednisolone\n2mg/kg (qd×1d)\nPreop\n    Glumac 2021\n\n62\nPlacebo\n \n\n    \n54\nDexamethasone\n0.1mg/kg (qd×1d)\nPreop\n    Sauer 2014\n\n370\nPlacebo\n \n\n    \n367\nDexamethasone\n1mg/kg (qd×1d)\nInduction\n    Ottens 2014\n\n138\nPlacebo\n \n\n    \n140\nDexamethasone\n1mg/kg (qd×1d)\nInduction\n    Whitlock 2015\n\n3752\nPlacebo\n \n\n    \n3755\nMethylprednisolone\n250mg (bid×1d)\nInduction|Intraop\n    Šakić 2015\n\n11\nControl\n \n\n    \n17\nDexamethasone\n8mg (qd×1d)\nIntraop\n    Mardani 2013\n\n50\nPlacebo\n \n\n    \n43\nDexamethasone\n8mg (tid×3d)\nInduction|Postop-prev\n    Dieleman 2012\n\n2247\nPlacebo\n \n\n    \n2235\nDexamethasone\n1mg/kg (qd×1d)\nInduction\n    \n      Before-After/Time Series\n    \n    Ushida 2009\n\n41\nMethylprednisolone\n2000mg \nPostop-treat\n    \n81\nMethylprednisolone\n2500mg \nIntraop|Postop-treat\n    \n      Case-Control\n    \n    Choi 2019\n\n16\nMethylprednisolone\n1.5mg/kg (qd×28d)\nPostop-treat\n    \n42\nMethylprednisolone\n1.5mg/kg (qd×28d)\nPostop-treat\n  \n  \n    \n      Intraop: intraoperative; Preop:preopertive; Postop: postoperative; prev:preventive.\n    \n  \n  \n\n\n\n\n\n\n\nNSAIDs\n Table 8. Studies examining NSAIDs, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n      NSAIDs\n    \n    \n  \n  \n    \n      Study\n      N\n      Drug\n      Dosing\n      Timing\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    Zhu 2018\n\n82\nPlacebo\n \n\n    \n81\nCelecoxib\n200mg (bid×7d)\nPreop\n    Zhou 2019\n\n60\nNone\n \n\n    \n60\nFlurbiprofen\n50mg (qd×1d)\nPreop\n    \n60\nFlurbiprofen\n50mg (qd×1d)\nIntraop\n  \n  \n    \n      Intraop: intraoperative; Preop:preopertive; Postop: postoperative; prev:preventive.\n    \n  \n  \n\n\n\n\n\n\n\nMultiple\n Table 9. Studies examining multiple drugs, dose, and timing according to study design. \n\n\n\n\n\n\n  \n    \n      Various\n    \n    \n  \n  \n    \n      Study\n      N\n      Drug\n      Dosing\n      Timing\n    \n  \n  \n    \n      Retrospective Cohort\n    \n    Jeong 2016\n\n275\nNone\n \n\n    \n200\nVarious\n \nPreop\n    Mangusan 2015\n\n36\nZolpidem\nNR\nPostop\n    \n232\nAny benzodiazepine\nNR\nPostop\n    \n287\nKetorolac\nNR\nPostop\n  \n  \n    \n      Preop:preopertive; Postop: postoperative."
  },
  {
    "objectID": "kq5.html#outline",
    "href": "kq5.html#outline",
    "title": "KQ 5: Potentially Inappropriate Medications",
    "section": "Outline",
    "text": "Outline\nKey question Included Studies Table 1. Number of included studies according to age and design. Design, centers, country, surgery Outcomes  Patient-reported     Outcome One     DAG if relevant     Relevant characteristics table(s) of studies     Results     Pooled  Clinical     Outcome One     DAG if relevant     Relevant characteristics table(s) of studies     Results     Pooled     Synthesis other Study/Participant Detail     Study Characteristics     Patient Characteristics Funding and Conflict of Interest Risk of Bias References"
  },
  {
    "objectID": "kq4.html",
    "href": "kq4.html",
    "title": "KQ 4 Intravenous vs. Inhaled Anesthesia",
    "section": "",
    "text": "Among patients 65 years or older [geriatric] undergoing surgery with general anesthesia, does the use of intravenous agents for maintenance of anesthesia improve postoperative outcomes compared with inhaled agents?"
  },
  {
    "objectID": "kq4.html#outcome-importance-rankings",
    "href": "kq4.html#outcome-importance-rankings",
    "title": "KQ 4 Intravenous vs. Inhaled Anesthesia",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "kq6.html",
    "href": "kq6.html",
    "title": "K6: Delirium Prophylaxis",
    "section": "",
    "text": "Among [geriatric] patients 65 years or older undergoing surgery and anesthesia, do dexmedetomidine, ketamine, ramelteon, or melatonin administered during the perioperative period decrease the risk of postoperative delirium or other adverse cognitive outcomes?"
  },
  {
    "objectID": "kq6.html#outcome-importance-rankings",
    "href": "kq6.html#outcome-importance-rankings",
    "title": "K6: Delirium Prophylaxis",
    "section": "Outcome Importance Rankings",
    "text": "Outcome Importance Rankings\n Table 1. Rankings of the 5 most important outcomes (10 respondents)."
  },
  {
    "objectID": "kq6.html#included-studies",
    "href": "kq6.html#included-studies",
    "title": "K6: Delirium Prophylaxis",
    "section": "Included Studies",
    "text": "Included Studies\n Table 2. Number of studies by design. \n\n\n\n\n\n\n\n  \n    \n    \n  \n  \n  \n    \n      Design\n      Studies\n    \n  \n  \n    Randomized Clinical Trial\n77\n    Before-After/Time Series\n2\n    Prospective Cohort\n1\n    Total\n80"
  },
  {
    "objectID": "kq6.html#design-centers-country-surgery",
    "href": "kq6.html#design-centers-country-surgery",
    "title": "K6: Delirium Prophylaxis",
    "section": "Design, centers, country, surgery",
    "text": "Design, centers, country, surgery\n Table 3. Study design, enrollment, centers, country, and surgery (see References for citations). \n\n\n\n\n\n\n\n  \n  \n    \n      ID\n      Study\n      Centers\n      Enrolled\n      Countrya\n      Surgeryb\n    \n  \n  \n    \n      Randomized Clinical Trial\n    \n    4914\nLi 2021\n\n1\n20\nChinaa\n\n    18\nShi 2019\n\n3\n168\nChinaa\nCardiac\n    24\nYang 2017\n\n2\n285\nChinaa\nCardiac\n    181\nHudetz 2009\n\n1\n78\nUSA\nCardiac\n    1819\nGao 2020\n\n1\n60\nChinaa\nCardiac\n    1847\nHudetz 2009\n\n1\n58\nUSA\nCardiac\n    2173\nMomeni 2021\n\n1\n420\nBelgium\nCardiac\n    2288\nDjainai 2016\n\n1\n185\nCanada\nCardiac\n    2396\nShehabi 2009\n\n2\n306\nAustralia\nCardiac\n    2624\nSubramaniam 2019\n\n1\n140\nUSA\nCardiac\n    5189\nSiripoonyothai 2021\n\n1\n75\nThailand\nCardiac\n    5269\nGao 2021\n\n1\n40\nChinaa\nCardiac\n    7240\nChitnis 2022\n\n1\n70\nCanada\nCardiac\n    9256\nJavaherforoosh 2021\n\n1\n60\nIrana\nCardiac\n    9741\nShi 2021\n\n1\n297\nChinaa\nCardiac\n    13171\nMahrose 2021\n\n1\n110\nEgypta\nCardiac\n    13406\nZhou 2019\n\n1\n156\nChinaa\nCardiac\n    13579\nAzeem 2018\n\n1\n70\nEgypta\nCardiac\n    13777\nGe 2016\n\n1\n50\nChinaa\nCardiac\n    16008\nTuran 2020\n\n6\n798\nUSA\nCardiac\n    16023\nWu 2020\n\n1\n80\nChinaa\nCardiac\n    16558\nFord 2020\n\n2\n210\nAustralia\nCardiac\n    335\nvan Norden 2021\n\n1\n63\nGermany\nCardiac:GI/Abdominal\n    1937\nHollinger 2021\n\n2\n200\nSwitzerland\nCardiac:Gyn:Ortho:Thoracic:Vasc\n    889\nChen 2020\n\n1\n88\nChinaa\nGI/Abdominal\n    1288\nDu 2019\n\n1\n87\nChinaa\nGI/Abdominal\n    1919\nXin 2021\n\n1\n60\nChinaa\nGI/Abdominal\n    5024\nLi 2015\n\n1\n100\nChinaa\nGI/Abdominal\n    5436\nChen 2013\n\n1\n126\nChinaa\nGI/Abdominal\n    12900\nTang 2021\n\n1\n100\nChinaa\nGI/Abdominal\n    13361\nWang 2020\n\n1\n110\nChinaa\nGI/Abdominal\n    13734\nFan 2017\n\n1\n76\nChinaa\nGI/Abdominal\n    13941\nMohamed 2014\n\n1\n58\nEgypta\nGI/Abdominal\n    8558\nLu 2021\n\n13\n808\nChinaa\nGI/Abdominal:Hepatic\n    15285\nBornemann-Cimenti 2016\n\n1\n60\nAustria\nGI/Abdominal:Hepatic\n    1817\nZhang 2019\n\n2\n464\nChinaa\nGI/Abdominal:Neuro:Thoracic:Urol\n    2318\nSu 2016\n\n2\n700\nChinaa\nGI/Abdominal:Neuro:Thoracic:Urol\n    5480\nZhang 2021\n\n1\n174\nChinaa\nGI/Abdominal:Neuro:Urol\n    6735\nSun 2022\n\n1\n80\nChinaa\nGI/Abdominal:Oralmax\n    13483\nWang 2019\n\n1\n198\nChinaa\nGI/Abdominal:Ortho:Thoracic\n    261\nLee 2018\n\n1\n354\nSouth Korea\nGI/Abdominal:Urol\n    5251\nChawdhary 2020\n\n1\n87\nIndiaa\nGyn:GI/Abdominal:Headneck:Ortho:Thoracic:Urol\n    328\nZhang 2018\n\n1\n120\nChinaa\nHeadneck\n    5240\nHong 2021\n\n2\n712\nChinaa\nNeuro:Ortho\n    1117\nMansouri 2019\n\n1\n150\nIrana\nOptho\n    2217\nRascon-Martinez 2016\n\n1\n80\nMexicoa\nOptho\n    1625\nWang 2020\n\n1\n44\nChinaa\nOralmax\n    5452\nGuo 2015\n\n1\n184\nChinaa\nOralmax\n    602\nFan 2017\n\n1\n148\nChinaa\nOrtho\n    742\nLi 2019\n\n1\n164\nChinaa\nOrtho\n    1267\nMei 2020\n\n1\n415\nChinaa\nOrtho\n    1419\nLiu 2016\n\n1\n200\nChinaa\nOrtho\n    1735\nMei 2018\n\n1\n336\nChinaa\nOrtho\n    2578\nLee 2015\n\n1\n56\nSouth Korea\nOrtho\n    2748\nLee 2018\n\n1\n132\nSouth Korea\nOrtho\n    3130\nLu 2017\n\n1\n152\nChinaa\nOrtho\n    5147\nZhang 2020\n\n1\n240\nChinaa\nOrtho\n    5164\nSultan 2010\n\n1\n222\nEgypta\nOrtho\n    11129\nZhu 2021\n\n1\n187\nChinaa\nOrtho\n    13075\nXing 2021\n\n1\n110\nChinaa\nOrtho\n    13184\nTu 2021\n\n1\n80\nChinaa\nOrtho\n    13630\nXuan 2018\n\n3\n453\nChinaa\nOrtho\n    16303\nYan 2021\n\n1\n100\nChinaa\nOrtho\n    16552\nde Jonghe 2014\n\n3\n452\nNetherlands\nOrtho\n    69\nHuyan 2019\n\n1\n360\nChinaa\nThoracic\n    3046\nHu 2021\n\n1\n177\nChinaa\nThoracic\n    3391\nShi 2020\n\n1\n106\nChinaa\nThoracic\n    13301\nLi 2020\n\n1\n87\nChinaa\nThoracic\n    13568\nHe 2018\n\n1\n90\nChinaa\nThoracic\n    13731\nYu 2017\n\n1\n92\nChinaa\nThoracic\n    4798\nDing 2015\n\n1\n40\nChinaa\nUrol\n    7151\nWang 2022\n\n1\n125\nChinaa\nUrol\n    2022\nDeiner 2017\n\n10\n429\nUSA\nVarious\n    2314\nSun 2019\n\n1\n618\nChinaa\nVarious\n    2866\nAvidan 2017\n\n5\n746\nUSA\nVarious\n    3716\nZhao 2020\n\n1\n432\nChinaa\nVarious\n    13512\nGupta 2019\n\n1\n100\nIndiaa\nVarious\n    \n      Before-After/Time Series\n    \n    693\nHokuto 2020\n\n1\n309\nJapan\nHepatic\n    2997\nMiyata 2017\n\n1\n82\nJapan\nThoracic\n    \n      Prospective Cohort\n    \n    9616\nBarreto Chang 2022\n\n1\n98\nUSA\n\n  \n  \n    \n      GI: gastrointestinal; Ortho: orthopedic; Neuro: neurological; Oralmax: oral maxillofacial; Vasc: vascular.\n    \n  \n  \n    \n      a Non very high Human Development Index country.\n    \n    \n      b Various indicates more than 4 different types of surgery."
  }
]